

The cost of the COVID-19 pandemic vs the cost-effectiveness of mitigation strategies in the EU/UK/EEA and OECD countries: a systematic review

Constantine Vardavas¹, Konstantinos Zisis^{1,2}, Katerina Nikitara¹, Ioanna Lagou¹, Katerina Aslanoglou¹, Kostas Athanasakis², Revati Phalkey³, Jo Leonardi-Bee³, Esteve Fernandez⁴, Orla Condell⁵, Favelle Lamb⁵, Frank Sandmann⁵, Anastasia Pharris⁵, Charlotte Deogan⁵, Jonathan E. Suk^{5*}

Author affiliations

1: School of Medicine, University of Crete, Heraklion, Greece

2: Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece

3: Centre for Evidence Based Healthcare, School of Medicine, University of Nottingham, Nottingham, UK

4: Catalan Institute of Oncology, Barcelona, Spain

5: European Centre for Disease Prevention and Control (ECDC)

***Corresponding Author:**

Jonathan Suk PhD

European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01

Email: jonathan.suk@ecdc.europa.eu

ABSTRACT

Objectives: COVID-19 poses a threat of loss of life, economic instability, and social disruption. We conducted a systematic review of published economic analyses to assess the direct and indirect costs of the SARS-CoV-2 pandemic, and to contrast these with the costs and the cost-benefit of public health surveillance, preparedness, and response measures in averting and/or responding to SARS-CoV-2 pandemic.

Setting: A systematic literature review was conducted to identify peer-reviewed articles estimating the cost of the COVID-19 pandemic and the cost-effectiveness of pharmaceutical or non-pharmaceutical interventions in EU/EEA/UK and OECD countries, published from the 1st of January 2020 through 22nd April 2021 in Ovid Medline and EMBASE. The cost-effectiveness of interventions was assessed through a dominance ranking matrix approach. All cost data were adjusted to the 2021 Euro, with interventions compared with the null.

Primary and secondary outcome measures: Direct and indirect costs for SARS-CoV-2 and preparedness and/or response or cost-benefit and cost-effectiveness were measured.

Results: We included data from 41 economic studies. Ten studies evaluated the cost of COVID-19 pandemic, while 31 assessed the cost-benefit of public health surveillance, preparedness, and response measures. Overall, the economic burden of SARS-CoV-2 was found to be substantial for both the general population and within specific population subgroups. Community screening, bed provision policies, investing in personal protective equipment and vaccination strategies were cost-effective, in most cases due to the representative economic value of below acceptable cost-effectiveness thresholds. Physical distancing measures were associated with health benefits; however, their cost-effectiveness was dependent on the duration, compliance and the phase of the epidemic in which it was implemented.

Conclusions: SARS-CoV-2 is associated with substantial economic costs to healthcare systems, payers, and societies, both short term and long term, while interventions including testing and screening policies, vaccination and physical distancing policies were identified as those presenting cost-effective options to deal with the pandemic, dependent on population vaccination and the R_e at the stage of the pandemic.

MAIN TEXT

INTRODUCTION

In the aftermath of significant outbreaks since the beginning of the 21st century, including among others those of Ebola, avian influenza (H5N1, H7N9), the 2009 H1N1 influenza virus pandemic, Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), it was acknowledged that large-scale infectious disease outbreaks represent a menace for loss of life, economic disturbance, and social disruption (1). The most recent pandemic caused by SARS-CoV-2 has undoubtedly hit hard on societies and healthcare systems. According to the situation update conducted by ECDC, as of week 17 of 2022, 512 690 034 cases of COVID-19 have been reported, including 6 252 316 deaths (2). To mitigate the pandemic and given the lack of preventative treatments until the rollout of vaccines in late 2020, governments worldwide implemented various non-pharmaceutical interventions (NPIs). These measures included personal protective, environmental, and physical distancing strategies as well as travel restrictions (3) which have been loosened and reinforced depending on the variation of the epidemiological situation (4), leading to an unprecedented decline in global economic activities and an economic burden both from direct costs of the NPIs and indirect costs. The closure of businesses led to significant disruptions to the global value chains in the first quarter of 2020 through increased unemployment rates, revenue loss, and a sharp decrease in personal incomes while the earlier action of NPIs implementation contributed to reduced economic impact as was shown in a study assessing the short-term economic consequences of the first-wave Covid-19 pandemic (5).

In the US, the cost of the COVID-19 pandemic has been estimated at \$13tn for the first 20 weeks of the pandemic (90% of the country's annual GDP) when drastic NPIs were predominately implemented, and approximately half of that figure corresponds to the projected 10-year decline in GDP attributable to the pandemic (6). Additionally, the global cost of the COVID-19 crisis has been estimated at 14% of 2019 GDP (around 12,206 mm\$), while for Europe, it is even higher: 16% for the Eurozone and 19% for the UK (7). Considering the cost-effectiveness of NPIs, in a recent systematic review and meta-analysis conducted by Zhou et al. (2021), the pooled incremental net benefit (INB) for NPIs was estimated at \$972·05, with subgroup analyses indicating the highest pooled INBs were for screening (\$2390·89) and suppression (\$2156·00) interventions (8).

Robust national preparedness and response strategies require recent data on the health impacts and the economic burden of respiratory infectious disease outbreaks in contrast to those associated with emergency response and preparedness actions. This evidence will ensure well-informed decisions regarding the proper allocation of resources (9, 10), information relevant not only for the COVID-19 pandemic but also for future pandemics.

This systematic review aims to a) summarise the total direct and indirect costs of the COVID-19 pandemic across EU/EEA/UK and OECD countries, and b) to contrast with the costs and the cost-benefit of public health surveillance, preparedness, and response measures in averting and/or responding to COVID-19 pandemic in this setting.

METHODS

Search strategy and selection criteria

A systematic review was conducted to identify peer-reviewed articles published from the 1st January 2020 through 22nd April 2021 in Ovid Medline and EMBASE. The review is reported adhering to the PRISMA framework (Preferred Reporting Items for Systematic Reviews and Meta-analyses) (11) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (12). Two sets of inclusion criteria were used to determine the eligibility of the studies based on the two objectives; however, a single search strategy was used to capture eligible studies. The complete search strategy and search terms is available in **Online Supplementary Appendix 1**.

The inclusion criteria for Objective 1: To summarise the total direct and indirect costs of the COVID-19 pandemic) were as follows:

- ✓ Population: EU/EEA/UK and remaining OECD countries
- ✓ Exposure: COVID-19 outbreak or public health preparedness measures or interventions.
- ✓ Outcome measures: direct and indirect costs for disease and preparedness and/or response.
- ✓ Perspective: All direct and indirect costs were considered pertaining to all relevant perspectives (e.g., individual, health and social care, and societal- including national and regional).
- ✓ Study designs: We included all relevant analytical epidemiological designs which estimate cost, including partial cost evaluation studies, cost studies, cost-outcome description studies, cost-description studies, and economic modelling studies.

The inclusion criteria for Objective 2: To contrast with the costs and the cost-effectiveness of public health surveillance, preparedness, and response measures in averting and/or responding to COVID-19 were as follows:

- ✓ Population: EU/EEA/UK and remaining OECD countries
- ✓ Intervention: Public health preparedness measures or interventions.
- ✓ Comparator: (i) No intervention (cost of inaction) or current practice; (ii) cost of preparedness vs cost of response (for studies reporting cost and benefit of public health preparedness).
- ✓ Outcome measures: Cost-benefit and cost-effectiveness outcomes (e.g., cost per life-year saved). Studies that use other methods to formally combine cost and clinical outcome data (pertinent to infectious diseases) were also included. Typical outcome measures of economic evaluations include: Life years gained (or cost per life-year achieved with the intervention under investigation when incremental costs are combined), Quality-Adjusted Life Years (cost per QALY gained), Cases averted (e.g., cost per case that is averted with the intervention versus the comparator) and monetary outcomes (in the case of a cost-benefit analysis). Where available the incremental cost-effectiveness ratio (ICER) was also provided.
- ✓ Perspective: All direct and indirect costs were considered pertaining to all relevant perspectives (e.g., individual, health and social care, and societal- including national and regional).
- ✓ Study designs: We included all designs specific to cost benefit questions either as full economic evaluation studies, including cost-minimization, cost-effectiveness, cost-utility and cost-benefit analyses; cost-outcome and economic modelling studies; or partial economic evaluations

Data analysis and extraction

Studies identified from the searches were uploaded into a bibliographic database (Covidence) in which duplicate entries were removed. Initially, a random sample of 100 titles and abstracts were screened independently for eligibility by two reviewers to enable consistency in screening and identify areas for amendments in the inclusion criteria. Since a high measure of inter-rater agreement was achieved (inter-rater agreement = 88.7%), the remaining titles and abstracts were screened for eligibility by one reviewer. Full-text articles of potentially eligible studies were retrieved and screened independently by two reviewers (inter-rater agreement = 89.3%). Data were extracted with the use of a predefined data extraction sheet. Initially, two reviewers piloted the data extraction template independently on a random sample of five included studies, and given the high consistency in data extraction, the remaining studies

were extracted only by one reviewer. Disagreements in every step of the process were subsequently discussed with a third reviewer and agreed upon.

Appraisal of methodological quality

The Consensus on Health Economic Criteria (CHEC) checklist was used (13) to evaluate the methodological quality of full health economic evaluations, which comprises of 19 questions with answers of “Yes” or “No”. For each positive response of full health economic evaluations, a single point was assigned for the methodological quality, with a maximum score of 19. For the quality appraisal of partial economic evaluations, we used items from the CHEC checklist that was applicable – hence the maximum score was 17. In cases of insufficient information or details reported in both full and partial economic evaluation studies, with regard to a specific item, no point was awarded for that question. Studies were categorised as high (>80%), good (60%–80%), medium (40%–60%), or low (<40%) quality. The quality appraisal process was completed by one reviewer, since piloting of three studies by two independent reviewers had an inter-rater agreement of 85.6%.

Comparative economic analysis approach

All cost data were adjusted to a common currency (Euro in 2021) and price year, using the Campbell and Cochrane Economics Methods Group–Evidence for Policy and Practice Information and Coordinating Centre cost converter (13). A two-stage computation is used, where the 2021 implied conversion factor is US \$1 = € 0.88. The 2021 implied conversion factor of British pounds is £1 = € 1.18. In our study, we first inflated the cost from the original price year to 2021, using a Gross Domestic Product deflator index (GDP values), obtained from the International Monetary Fund World Economic Outlook Database GDP deflator index data set. After that, we converted the original currency to the next rounded 2021 Euros, using conversion rates based on Purchasing Power Parities for GDP (PPP values). For studies that did not state the year of cost calculation, the costs were calculated one year before the publication year.

Synthesis of cost-effectiveness

The Dominance Ranking Matrix (DRM) was used to assess the cost-effectiveness of the interventions noted within the identified studies (14). The DRM is a three-by-three matrix with the following classification options:

(a) Strong dominance for the intervention when the incremental cost-effectiveness measure shows the intervention vs. the comparator is (i) more effective and less costly; or (ii) as effective and less costly; or (iii) equally costly and more effective. Strong dominance suggests that under the similar circumstances, the intervention is preferable to the comparator.

(b) Weak dominance for the intervention vs. the comparator is noted when the measure shows the intervention as (iv) equally costly and effective; or (v) more effective and more costly; or (vi) less effective and less costly. In principle weak dominance indicates that no conclusion can be drawn and hence judgment by policymakers is required on whether the intervention is preferable when taking into consideration whether the cost/benefit tradeoffs are worth the introduction of the intervention within the particular context.

(c) Non-dominance for the intervention vs. the comparator when the measure shows the intervention as (vii) more costly and less effective; or (viii) equally as costly and less effective; or (ix) more costly and as effective. In this case the comparator is preferable to the measured intervention, at least under the circumstances of the specific study.

Patient and public involvement

This study was performed under contract for the European Center for Disease Prevention and Control (ECDC). Patients or the public were not explicitly involved in the design, or conduct, or reporting, or dissemination plans of our research.

RESULTS

10,314 non-duplicate studies were identified, of which 403 proceeded to full text screening with 362 full text studies were excluded for the following reasons: inadequate data on costs and/or cost-effectiveness (n=269), reviews/editorials/perspectives/views/opinion papers (n=68), not referring to outbreaks of Covid-19 infectious disease (n=23), and no full text available (2). Subsequently, 41 studies met all inclusion criteria and were included in the systematic review (**Figure 1**).

Approximately half of the studies (20/41) were of high methodological quality, ten had good quality, and the remaining 11 studies were of medium quality (**Online Supplementary Appendix 2**). Lower scores were mainly due to missing information relating to the comparative intervention, lack of sensitivity analysis, not reporting incremental costs among comparative interventions (since in some studies alternative strategies were not included).

Objective 1: Economic impact of COVID-19 infection to healthcare systems and societies

Ten studies evaluated the cost of the COVID-19 pandemic within EU/EEA/UK and OECD countries (**Table 1**), among which eight studies used a cost of illness analysis approach (15-22). The direct medical costs were presented in seven out of ten studies (15-17, 19, 20, 22, 23), while in eight studies the costs were estimated for a time horizon shorter than one year (16-18, 20-24), and specific discount rates were not applied in seven studies (15-17, 20, 22-24). With regards to the country of origin, five out of the ten studies took place in the European region, including in the UK and Turkey (15-19), three were from the USA (20-22), one from Korea (23) and one from Australia (24). Six of the 10 studies were observational (17-20, 22, 23), while a few used modelling techniques (15, 16, 24) or simulation methods (21). Furthermore, it should be noted that the healthcare system perspective was included in the analysis of four studies (15, 16, 21, 22), the societal in two (17, 18), the third payer perspective was assessed in three (19, 21, 23), and one study (24) assessed data from the public health payer perspective. The perspective considered within onestudy was unclear (20).

Overall economic burden on the population and to the healthcare system

Overall, the economic burden of COVID-19 pandemic was found to be substantial (**Table 2**). The socioeconomic implications of COVID-19 in Italy, appraised by Nurchis et al. (2020) (18) through a cost of illness analysis of indirect costs, showed a temporary productivity loss reaching 114,120,531 € for 110,868 cases (1,029 € per case). Individuals at the age of > 40 years old were found to be affected the most. Furthermore, the permanent productivity losses were estimated at 333,063,591 € for 3,926 deaths (84,836 € per death) with ages >50 years old to consistently having higher indirect costs due to death. Bartsch et al. (2020) (19) at the start of the pandemic, when no vaccines were available showed that the more people infected, the higher medical costs are presented using a Monte Carlo simulation model to highlight the devastating impact of the pandemic on the US healthcare system and third payers. In the case of 20% of the US population to be infected with COVID-19 over the course of the pandemic (and not accounting for reinfections), the total costs accrued were estimated at 129.8 billion € and reaching 170.3 billion € including post discharge costs after one year. In the case that 80% of the US population is infected, the direct medical costs reached an estimated 519.4 billion €, and 682.6 billion € with the post discharge costs after one year of infection. Mallow et al. (2021) (24) assessed the value of statistical life in a total of 6 429 deaths in Ohio USA, where the economic burden of premature deaths was estimated at 13.8 billion € as of 30 November 2020. Additional analyses have been performed by Kirigia et al. (2020) (21) using the human capital approach to estimate the total present value of human

lives lost due to COVID-19 in the UK as of July 2, 2020. Notably, the value for 43 906 lives lost approached 7.8 billion € at a 3% discount rate with, approximately 76.2% of the total present value sustained by those aged 30 - 79 years. Lee et al. (2020) (20) aimed to determine the hospitalisation periods and medical costs among 145 hospitalised children with COVID-19 in Korea. According to the results, the estimated medical expenses reached 252,389 € totally and increased per age as 54 patients in the ages of 16-19y accounted for 156,738 € (more than 60% of the total cost) and per patient at 2 903€ for a mean hospitalization period of approximately 10 days, indicating that these ages contributed to higher costs than younger ages included in the study.

DiFusco et al. (2021) (22) by conducting a cost of illness analysis to estimate the direct medical costs of inpatient setting for a time horizon of 8 months, showed that the mean total of hospital costs related to COVID-19 was 19,513 € for 8.3 mean hospital length of stay days (LOS) (SD 9.1). Higher costs were presented for those people treated in the ICU, reaching a mean cost of 20,400€, which represent 21,850€ in case of ICU usage without invasive mechanical ventilation (IMV) for a mean LOS of 9.1 days and estimated at a mean cost of 62,139€ if both ICU and IMV are used for mean LOS of 18.6 days.

Moreover, Gedik et al. (2020) (23) performed a simple cost-analysis of COVID-19 patients in Turkey and showed that the mean cost per ICU patient was much higher than clinical patients in wards and particularly estimated at 2,322 € for mean hospitalization days of 14.7 compared to 700. € for 9 mean hospitalization days.

Overall economic burden to specific population subgroups

With regards to the costs for specific sub-populations, Degeling et al. (2021) (15) estimated the health and economic impacts of delays in treatment initiation of 65,415 cancer cases (breast cancer, colorectal cancer, lung cancer and melanoma) due to COVID-19 infection in Australia. Apart from the excess deaths and life-years lost, costs to the health care system exceeded more than 6 million € for the 3-month delay while more than 25 million € for a 6-month delay. Czernichow et al. (2021) (16) identified a strong relationship between obese and overweight patients (BMI 25.0 to ≥ 40) with increased direct medical costs of secondary care related to COVID-19 across the EU, UK and EFTA countries, with 44% of the total treatment costs of COVID-19 in Europe to be associated with those populations (due to the higher probability of being hospitalized, a longer length of stay, and higher risk of severe outcomes). The total costs of 14.2 billion € were the total secondary medical care costs for a 6-month time horizon

analysis, with cases with a BMI ≥ 40 accounting for the highest direct costs per case. In a similar study conducted by Bain et al. (2021) (17), whose aim was to estimate the impact of diabetes on the total secondary care costs of COVID-19 and for the same timeframe and population numbers in regards to the same European countries, poor glycaemic control was associated with excess direct medical costs of secondary care due to COVID-19 infection, estimated at 400.4 million € for 6 869 hospitalizations of Type 1 diabetes cases and 1,498 billion € for 31 701 hospitalizations of Type 2 diabetes cases.

Objective 2: Economic evaluation of strategies for the mitigation of COVID-19 virus transmission

Our systematic review identified 31 studies assessing the cost-effectiveness of interventions for reducing SARS-CoV-2 transmission within EU/EEA/UK and OECD countries (**Table 3**). We identified studies that assessed isolation, lockdown policies, physical distancing scenarios (25-35), testing/screening policies (36-42), personal protective equipment intervention (43), vaccinations (44-47) and pharmaceutical treatment strategies (n=4) (47-50). Multiple strategies were evaluated by four studies (51-54), that mainly assessed the combination of testing, isolation, and vaccinations, and one study (55) analysed an ICU bed provision scenario.

Concerning study characteristics, thirteen out of 31 studies were from the USA (25, 26, 36, 38, 40, 41, 44-46, 48, 50, 52, 54), seven from the UK (30-33, 42, 49, 53), three from Germany (28, 51, 55), one from Switzerland (47), Israel (34), and Wales (37), while five of these studies included analyses for multiple OECD countries (27, 29, 35, 39, 43). The societal perspective was followed in 14 studies (26, 28, 30, 31, 33, 34, 36, 39, 41, 43, 51, 52, 54, 55), while 9 studies performed an analysis via a healthcare perspective (25, 27, 37, 38, 40, 42, 46, 47, 49, 53). Various perspectives were included in 4 studies (44, 45, 48, 50), including the payer for some of them (45, 48, 50), while the perspective considered was unclear in three studies (29, 32, 35).

Cost-effectiveness of testing & screening policies

Seven studies (**Table 4**) assessed the cost-effectiveness of testing and screening interventions. Stevenson et al. (2021) (42) compared 30 interventions and found that the least costly testing intervention was testing on hospital admission, and routine retesting following hospital admission. The authors noted that strategies with shorter times to test results were more cost-effective, all other things being equal, as were SARS-CoV-2 tests with greater diagnostic accuracy. strategies that included saliva sampling and nasopharyngeal have been assessed within the systematic review and meta-analysis by Bastos et al. (2021) (39). The incremental cost per additional SARS-CoV-2 infection detected with nasopharyngeal

swabs versus saliva sampling was 6,427 € if the prevalence was 1%, and the cost-savings of saliva sampling were estimated at 505,177 € (95% CI 371,217- 660,568) if 100 000 persons are tested. The clinical and economic value of PCR testing was investigated by Neilan et al. (2020) (38), who showed that under all epidemic growth scenarios considered, testing people with any COVID-19-consistent symptoms would be cost-saving compared to restricting testing to only those with symptoms severe enough to warrant hospital care, leading to lower costs and reducing infections and deaths. According to their results, and within the context of the first wave of the pandemic, the symptomatic and asymptomatic monthly testing scenario was a cost-effective strategy only with an (R_e) > 1.6 but would be no longer cost-effective option for lower reproduction scenarios, unless testing cost was lower. . A cost-minimization analysis performed by Currie et al. (2020) (37) comparing community testing undertaking swabbing of suspected cases in Wales with standard hospital testing showed that community testing for COVID-19 was a superior strategy, resulting in significant benefits for the healthcare system.

Two studies appraised the cost-effectiveness outcomes of different testing strategies within specific settings. Baggett et al. (2020) (40) investigated the clinical outcomes, costs, and cost-effectiveness associated with strategies for COVID-19 management among adults experiencing sheltered homelessness in Boston, USA. Daily symptom screening with subsequent PCR testing of individuals who screened positively was the most efficient strategy and was cost-saving relative to no intervention in all epidemic scenarios.

Paltiel et al. (2020) (41) examined the SARS-2 screening performance standards that would permit the safe return of students to US residential college campuses for the fall semester of 2020 and noted that screening with a less expensive, less sensitive test dominated the intervention of screening with more expensive, more accurate tests. Paltiel et al. (2021) (36), assessed the clinical and economic effects of widespread home-based SARS-CoV-2 antigen testing and noted that the cost per infection averted was 6,266 €.

Cost-effectiveness of quarantine, isolation, physical distancing, and physical restriction policies

Twelve studies were included to assess the cost-effectiveness across different strategies to prevent or mitigate SARS-COV-2 transmission (**Table 4**).

Kouidere et al. (2021) (35) conducted a mathematical compartmental modelling to assess three different strategies for diabetics and concluded that awareness programs and quarantine for those infected having symptoms as well as those having complications in hospitals with treatment was the most effective

strategy and associated with an incremental cost-effectiveness ratio (ICER) of -0.6951 (cost per infection averted) compared to sensitisation and prevention.

The cost-effectiveness of comparing the national lockdown policy for the susceptible population with the isolation of those infected or being at high risk in Israel returning to the workforce under social distancing measures after a 14-day isolation period was appraised by Shlomai et al. (2020) (34). The national lockdown of the susceptible population was associated with a higher economic burden but contributed to a reduction in deaths making this intervention superior to the comparator only in terms of health outcomes but was not cost-effective since it contributed to high economic costs, estimated at 36,568,451 € costs per death averted, and 3.6 million € costs per QALY gained. Furthermore, Keogh-Brown et al. (2020) (33) assessed the direct and indirect costs of three different strategies in the UK, and indicated that although mitigation and suppression policies contribute to lower mortality rates, the economic impact of COVID-19 is likely to be dominated by public prevention measures rather than the direct health costs of the disease and indicated that a three-month mitigation scenario resulted in a prediction of 13.5% loss to GDP with the direct-health related economic impact of 2% of the GDP while the suppression scenario was associated with an approximately 22% loss in GDP. Furthermore, Miles et al. (2020) within the context of a cost-benefit analyses (32) noted that a full lockdown policy for four months followed by an extension for three months showed that net extra economic costs of the lockdown relative to the easing of restrictions was estimated at 116.2 billion € with the best scenario of lives not lost at 96.5 billion €. The main factors of the substantial costs in lockdown policy were associated mainly with employment restrictions and physical restrictions. Miles et al (2021) also (31) conducted an additional modelling and simulation study to assess a few physical restriction scenarios in a timeframe of 6 months in the UK and found that the strategy of relatively slowly easing restrictions comes at a cost in terms of GDP reduction of up to 697,121 € /life-year saved. Moreover, the cost per life-year saved with a short transition physical restriction policy (8 weeks medium then 18 weeks low) was associated with a cost of per life-year saved at 206,888 € while keeping the policies strict for 26 weeks was estimated at a cost of per life-year saved of 1,553,988 €.

Suppression and physical distancing interventions was assessed by Zala et al. (2020) (30) and Barnett-Howell et al. (2021) (29). Zala et al., noted that suppression policies compared to an unmitigated scenario strategy was associated with an ICER below 56 972 €, while all of the four suppression policies presented ICER results. Barnett-Howell et al. (29) investigated five physical distancing strategies,

including an unmitigated intervention, to assess the value of statistical life lost. Full lockdown policies were associated with lower VSL in the US, UK and Mexico countries (US: 23 billion €, UK: 4.76 billion €, Mexico: 794 million €) while the no-action scenario, which was the unmitigated spread of COVID-19, contributed to higher VSL in those countries (US: 38.9 billion €, UK: 7.1 billion €, Mexico: 1.58 billion €).

Additional studies focusing on policies related to stay-home and shutdown orders, were investigated by Gandjour (2020) (28) and Thom et al. (2021) (27). Gandjour assessed the clinical and economic cost of a shutdown during the SARS-CoV-2 pandemic in Germany to estimate the cost of life-years gained per capita estimating the indirect costs for one year. The results showed that economic cost of the intervention of lockdown was associated with 3,472 € or extrapolated to the total population, 8% of Germany's GDP in 2019 (ranging from 1% to 12% in the sensitivity analysis). Thom et al. (27) provided an exploratory comparison of health-related benefits and costs saved by government mitigation measures across European countries (UK, Ireland, Germany, Spain and Sweden) over a timeframe of seven months, where the authors concluded that the benefit of government COVID-19 responses might outweigh their economic costs, saving millions of QALYs (0.5 million for Sweden to approximately 5 million for Germany) and ideally those countries with more mask-wearing and testing, had better outcomes.

The last studies focusing on stay-home policies were by the same authors, Chen et al., (2020) (25, 26). Their first study (25) estimated the total medical costs by keeping the US economy open and assessed 13 interventions with different stay home isolation and voluntary home isolation compliance rates for one year. Without mitigation, the total medical costs would be a 5% of the US GDP. In their second study (26), Chen et al compared the epidemiological and economic impact of COVID-19 spread in the US under different mitigation scenarios, comprising NPIs including stay-home with varying compliance rates. The study results indicated that the preferred mitigation scenario in terms of lives saved, and infections averted is when the compliance is at 90%, the stay at home duration is 45 days; with an economic impact of 2.76 trillion €.

Cost-effectiveness of vaccination measures

Three included studies (44-46) focused on vaccination interventions used modelling and simulation methods to assess the cost-effectiveness of the included interventions (**Table 4**). Shaker et al. (2021) (44) appraised the universal COVID-19 vaccination versus risk-stratified vaccination approach over the

timeframe of one year, and they found that the universal COVID-19 vaccination dominates the risk-stratified approach, making it a cost-effective strategy for the US population from the societal perspective and the healthcare perspective. ICER analyses indicated that in the case of societal perspective, the universal approach presents a cost of 52,033 € per death averted compared to the risk-stratified vaccination, with cost-savings estimated at 395 million €. When considering the healthcare perspective, the cost per death averted of the risk-stratified approach was 52,575 € making it the dominant option. Bartsch et al. (2021) (45) noted that that NPI implementation before vaccination was associated with less total costs compared to the case of non-implementation of NPIs. Finally, Kohli et al. (2021) (46) conducted a CUA to assess the COVID-19 vaccine vs. no vaccine for the US population over one year. Base case analysis presented good value for money outcomes where the ICER per age was found to be 74,652 € for ages 18-49 y, 6,353 € for 50-64 y while for ages 65 + the COVID-19 vaccine dominates. This strategy was also cost-effective under additional scenarios, such as with the per risk-based prioritisation scheme.

Cost-effectiveness of treatment measures

Our analysis included four studies (47-50) assessing pharmaceutical interventions (**Table 4**). Lee et al. (2021) (48) simulated the transmission spread of SARS-CoV-2 and the economic and clinical impact of the spread in the US over one year. The authors noted that starting treatment at an of $R_e 3-5$ was cost-effective and provided ICER results of 2,690 €/QALY saved from the societal perspective when treating 75% of symptomatic cases and treatment course costs 397 €, and $\leq 6,267$ €/QALY saved from the third-payer perspective when at least 50% of all patients were treated. The study also concluded that treating 25% or 50% of symptomatic patients at $R_e 2-5$ and at a treatment cost of 397 €, was also cost-effective. Across all R_e assessed, the net cost-savings were high from the third-payer perspective and even higher from the societal perspective. Sheinson et al. (2021) (50) assessed the cost-effectiveness of treating hospitalised COVID-19 patients with COVID-19 treatment vs. treating them with the best supportive care (BSC). Under the payer perspective, treatment of patients with COVID-19 was more cost-effective than BSC as it was associated with 15,784 € (with a FFS payment) and 18,593 € (with a bundled payment). The ICER results from a societal perspective were even better, making the COVID-19 treatment process a dominant strategy as treatment of patients with COVID-19 was associated with a cost of 6,508 € (with FFS payment) and 9,317 € (with bundled payment).

With regards to specific pharmaceutical regimens, Águas et al. (2021) (49) estimated that the incremental cost per life-year gained for dexamethasone treatment was 1,071 € compared to no treatment. On the contrary, within a cost-analysis performed by Vernaz et al. (2020) (47) compared standard care among pharmaceutical interventions including lopinavir/ritonavir and hydroxychloroquine (a pharmaceutical discussed early in the pandemic but not a legitimate treatment) for hospitalized patients with SARS-CoV-2 in Switzerland. The results highlighted the additional costs attributable to the length of stay presented a mean cost of 648,102 € for 93 patients.

Cost-effectiveness of bed provision policies

We identified one study indicating the scenario of increasing ICU bed availability. Gandjour et al. (2021) (55) performed a cost-effectiveness and return on investment (ROI) analysis and estimated that the provision of a staffed ICU bed reserve capacity was cost-effective even for a low probability of bed utilisation and estimated that the provision of 1 ICU bed would cost 14,306 € to 22,986 € per life-year gained, while the addition of 10,000 ICU beds provided cost 18,389 € to 29,627 € per life-year gained.

Cost-effectiveness of personal protective equipment strategies

Risko et al. (2020) (43) conducted a cost-effectiveness analysis indicating that investing in personal protective equipment (PPE) was a cost-effective option for 166 million simulated workers over a period of 7.5 months (**Table 4**). In general, they found that an investment of USD 9.6 billion (7.62 billion €, 2021) concerning the purchasing and distribution of PPE to allow for adequate protection of all HCWs was cost-effective and led to an ICER of cost per case averted at 57 €, and an ICER of cost per death averted of 4,159 €, which translates to 41.1 billion € (95% CI 39.6 to 42.6) in economic gains.

Cost-effectiveness of other combined strategies

The review included four studies (51-54) that assessed multiple combined interventions related to testing, isolation, vaccination and physical distancing strategies (**Table 4**). The value of immunisation alongside physical distancing policies was evaluated by Sandmann et al. (2021) (53), who assessed the clinical and economic value of COVID-19 vaccination in the UK and estimated that without the initial lockdown, vaccination, and increased physical distancing, 3.1 million (0.84 – 4.5) deaths would occur in the UK over ten years with a cost of 169 million €. The introduction of vaccination provided estimations of incremental net monetary values ranging from 13.7 billion € to 381.4 billion € in the best-case

scenario and from 1.25 billion € to 64.8 billion € in the worst-case scenario compared to no immunization –under the healthcare perspective. In regard to the wider societal perspective, where GDP income loss was included in the relevant analyses, the incremental net monetary value of introducing vaccination vs. no vaccination was found to be extremely positive across physical distancing scenarios. Pandey et al. (2021) (54) assessed the cost-effectiveness of eight testing measures in conjunction with isolation measures over a timeframe of five months. In cases of an $R_0=2$ and assuming the test cost of approximately 4 € and the societal willingness-to-pay (WTP) per year-life lost (YLL) averted of 79,417 €, the optimal strategy was daily testing plus a 2-week isolation. On contrary, at a lower R_0 (1.5 - 1.8) weekly testing plus 1-week isolation was found to be the optimal strategy. Furthermore, the weekly testing plus 2-week isolation was also optimal if $R_0 > 2$ (under the same assumptions and when the test costs < 318 €).

The combination of isolation with laboratory testing and self-screening in college campuses over 3.5 months was assessed by Losina et al. (2020) (52), who concluded that a comprehensive physical distancing policy with a mandatory mask-wearing policy can prevent most COVID-19 cases on college campuses and is relatively cost-effective. The last study that assessed multiple interventions was that of Ebigbo et al. (2021) (51) that appraised the use of low vs. high-risk PPE (masks, goggles, gloves and apron, and centralised laboratory-based testing) applied during routine pre-endoscopy procedures. The authors noted that routine pre-endoscopy testing combined with high-risk PPE becomes more cost-effective with rising prevalence rates of COVID-19 while in lower prevalence rates the dominant strategy appeared to be the intervention of point-of-care antigen test without routine high risk PPE use.

DISCUSSION

This systematic review aimed to assess the economic burden of COVID-19 infection to societies and healthcare systems and to assess the strategies used to prevent and mitigate COVID-19 outbreaks in the EU/UK/EEA and OECD countries from studies published through 22nd April 2021. Our findings indicate that the overall economic impact of the virus is substantial for individuals, healthcare systems and payers, while our review identified that NPIs and pharmaceutical measures, including ICU bed provision implemented within the context of the COVID-19 pandemic from both healthcare and societal perspectives and within one year time horizon are cost effective response and mitigation measures.

Overall, in the studies identified, the economic burden of COVID-19 pandemic was found to be substantial in all studies included in the systematic review, with both direct and indirect costs playing a significant role. Direct costs were primarily attributed to medical expenses from hospitalisations and ICU admissions while the indirect and societal costs yielded by NPIs, mainly from stay-home and isolation strategies, contributed to the further increase of economic costs and also resulted in a decrease in GDP. Moreover, the delays in treatment initiation of other diseases (e.g., cancer) were also found to have substantial economic impact. At the patient level, increased medical costs were also related to comorbidities such as obesity and diabetes. Regarding indirect costs, temporary and permanent productivity loss, as well as human lives lost due to COVID-19 were substantial.

The NPIs implemented for the pandemic control led to a benefit in life years in an individual or societal level compared to the no intervention scenario, although the cost benefit of such interventions differed depending on the perspective, the timeframe, the setting and the epidemiological situation of the pandemic. Considering the testing strategy, results were dependent on the cost per test and the R_0 at the time of assessment. Overall, low-cost repeated community screening was a cost-effective approach, in combination with other NPIs, especially when the cost of testing remains low and at higher R_e . As for lockdown strategies, studies showed that if performed early in the pandemic for a limited period of time and with sufficient compliance, they substantially could reduce the medical costs of COVID-19 from a healthcare perspective – especially prior to population immunisation. In general, mitigation scenarios resulted in less GDP loss compared to suppression ones. Finally, quarantine and physical distancing strategies were found to be effective for the containment of the COVID-19 pandemic, while it was indicated that with an increasing R , a combination of NPIs, including screening, physical distancing, and quarantine of contacts would be more efficient. With regards to PPMs they showed a benefit both in health and costs when used by HCWs, as also was the provision of ICU beds. Regarding pharmaceutical measures, vaccination was consistently found to be cost-effective, with the universal COVID-19 vaccination dominating the risk-stratified approach. Additionally, pharmaceutical treatments were also cost-effective when provided in scenarios of high transmissibility (high R_e). Finally, the combination of testing, vaccination, physical distancing measures and mask wearing was found to be cost saving, with a significant number prevented cases and deaths.

A systematic review on previous respiratory infectious disease outbreaks prior to COVID-19 (56) concluded to similar results by pointing out the significant burden of both direct and indirect medical costs for management and response activities. Most direct costs occurred from the additional personnel

hours, the response planning and contact tracing activities, the provision of training and educational materials and the laboratory costs. Indirect costs were greater than direct ones, particularly when school closures and/or workplace closures were implemented, due to lower productivity (56). However, given the strictness of the NPIs in COVID-19 pandemic the economic burden has been found to be high for primary production sectors including industries associated with activities in raw materials extraction, secondary industrial sectors involving the production of finished products and tertiary sectors encompassing service provision industries (57).

This systematic review provides a wide range of cost-effective options across comparative strategies implemented to prevent or mitigate virus transmission. Strategies, including vaccination measures (ideally universal vaccinations), screening policies (with the saliva sampling to be a cost-saving option compared to nasopharyngeal swabs) and expanding a staffed ICU bed reserve capacity were found to be dominant strategies against SARS-COV-2 transmission, indicating the cost-savings as well as the economic value of their implementation. An earlier systematic review by Vandepitte et al. (2021) also showed that frequent and universal testing activities are a cost-effective strategy, highlighting that it would have a greater impact if enacted in a setting with a high R_e . Moreover, they noted that PPM was also a cost-effective strategy depending on the compliance, the context, and the R_e . (58). Similarly in another review, contact tracing and isolation of cases was a cost-effective NPIs, along with adequate surveillance, PPM for healthcare professionals, and vaccination. Contrastingly, physical distancing strategies including school and workplace closures were found to be effective but costly, making them the least cost-effective options. Additionally, combined NPIs were more cost-effective than individual ones, while the significance of early implementation was emphasised (59).

Strengths and limitations

This review provides several strengths, including covering within one review both the economic burden of COVID-19 and the cost-effectiveness of the strategies and programs implemented to mitigate the pandemic. Moreover, this review followed a systematic approach to study identification, data extraction and quality appraisal with most of the included studies of good or high quality. Furthermore, this study used the Dominance Ranking Matrix approach, which summarised and interpreted the results of economic evaluation studies. On the other hand there are some limitations, as publication bias can not be excluded and as our search was performed up to the end of April 2021 it only reflects the cost-

effectiveness of interventions assessed during the first waves of the pandemic with the majority of the populations unvaccinated, while most studies have a short duration on which modelling was performed. A further limitation is that most studies estimate costs and benefits based on a health care perspective, excluding wider societal effects, with a time horizon of 1 year. As we restricted our search to EU/UK/EEA/US and OECD countries, the studies primarily refer to high-income countries. Finally, as costs and resources varied between different countries, different pandemic settings and over time, and as indicated in this review, dependent on multiple other factors including population vaccination status, preexisting healthcare capacity and the infectivity of the COVID-19 variant at each time point, the comparison of cost-effectiveness measures is a complex process to interpret and the cost effectiveness of each intervention should be weighed by policymakers against the regional circumstances. Moreover, as the complete economic and health consequences are yet unknown, further research is needed on the cost-effectiveness of NPIs, while the cost of the long-term effects of COVID-19 (both physical and mental) should be also assessed in future analyses.

CONCLUSION

This systematic review assessed economic evaluation studies concerning SARS-CoV-2 and the cost-effectiveness of strategies to prevent and mitigate virus spread within the EU/UK/EEA and OECD country context. Results of this study are based primarily on first wave of the pandemic and mostly from a health care perspective with a short time horizon; particularly within 1 year time horizon. Our review showed that SARS-CoV-2 is associated with substantial economic costs to healthcare systems, payers, and societies, both short term and long term, while interventions including testing and screening policies, vaccination and physical distancing policies were identified as those presenting cost-effective options to deal with the pandemic – dependent on population vaccination and the R_e at the stage of the pandemic. Policymakers could benefit from these findings as they indicate the value of both pharmaceutical and non-pharmaceutical interventions to mitigate and respond to the ongoing COVID-19 pandemic and in preparation for future respiratory pandemics.

ACKNOWLEDGEMENTS

We would like to thank Chrysa Chatzopoulou, Katerina Papathanasaki and Konstantinos Skouloudakis for contributing to file and data archiving and data management.

CONTRIBUTORS

CV, JLB, and JES designed the study. KN and KZ undertook the systematic review and extracted the data with help from KA, IL and KPA. JLB and RP developed the search strategy and JLB ran the searches. KZ and KA analysed and interpreted the economic data. OC, FL, FS, AP, CD, EF and JES participated in data evaluation and interpretation along with CV, JLB, RP, JES, KN, KZ, KA, and ST. Authors CV, KA and KZ wrote the first draft of the manuscript with input from all authors. All authors reviewed and revised subsequent drafts.

Declaration of interests

We declare no competing interests.

Funding

This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), to the PREP-EU Consortium, coordinated by Dr. Vardavas under specific contract ECD. 11986 within Framework contract ECDC/2019/001. The information and views in this manuscript are those of the authors and do not necessarily reflect the official opinion of the Commission/Agency. The Commission/Agency do not guarantee the accuracy of the data included in this study. Neither the Commission/Agency nor any person acting on the Commission's/Agency's behalf may be held responsible for the use which may be made of the information contained therein.

Data sharing statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

REFERENCES

1. Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al. *Disease Control Priorities: Improving Health and Reducing Poverty*. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2018 International Bank for Reconstruction and Development / The World Bank.; 2017.
2. ECDC. COVID-19 situation update worldwide, as of week 17, updated 5 May 2022. 2022
3. ECDC. Covid Statistic Measures 2021
4. ECDC. Latest risk assessment: further emergence and potential impact of the SARS-CoV-2 Omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 15 December 2021. 2021
5. Demirgüç-Kunt A, Lokshin M, Torre I. The sooner, the better: The economic impact of non-pharmaceutical interventions during the early stage of the COVID-19 pandemic. *Economics of Transition and Institutional Change*. 2021;29(4):551-73.
6. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *Jama*. 2020;324(15):1495-6.
7. López-Valcárcel BG, Vallejo-Torres L. The costs of COVID-19 and the cost-effectiveness of testing. *Applied Economic Analysis*. 2021;29(85):77-89.
8. Zhou L, Yan W, Li S, Yang H, Zhang X, Lu W, et al. Cost-Effectiveness of Interventions for the Prevention and Control of COVID-19: A Systematic Review and Meta-Analysis. *SSRN*. 2021;3944593.
9. Meltzer MI, Gambhir M, Atkins CY, Swerdlow DL. Standardizing scenarios to assess the need to respond to an influenza pandemic. *Clin Infect Dis*. 2015;60 Suppl 1(Suppl 1):S1-8.
10. WHO. *Definitions: Emergencies*. World Health Organization 2016. . 2016
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ*. 2013;346:f1049.
13. CCEMG. *EPPI-Centre Cost Converter*. 2019.
14. JB I. The systematic review of economic evaluation evidence. *Implement Sci*. 2014:1-24.
15. Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, et al. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. *Asia Pac J Clin Oncol*. 2021;17(4):359-67.
16. Czernichow S, Bain SC, Capehorn M, Bøgelund M, Madsen ME, Yssing C, et al. Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model. *Clin Obes*. 2021;11(2):e12442.
17. Bain SC, Czernichow S, Bøgelund M, Madsen ME, Yssing C, McMillan AC, et al. Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. *Curr Med Res Opin*. 2021;37(1):27-36.

18. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, et al. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. *Int J Environ Res Public Health*. 2020;17(12).
19. Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. *Health Aff (Millwood)*. 2020;39(6):927-35.
20. Lee JK, Kwak BO, Choi JH, Choi EH, Kim JH, Kim DH. Financial Burden of Hospitalization of Children with Coronavirus Disease 2019 under the National Health Insurance Service in Korea. *J Korean Med Sci*. 2020;35(24):e224.
21. Kirigia JM, Deborah Muthuri RNK. The Present Value of Human Lives Lost Due to COVID-19 in the United Kingdom. *Pharmaceutical and Biomedical Research*. 2020;6(3):237-46.
22. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *J Med Econ*. 2021;24(1):308-17.
23. Gedik H. The cost analysis of inpatients with COVID-19. *Acta Medica Mediterranea*. 2020(6):3289-92.
24. Mallow PJ. Estimates of the value of life lost from COVID-19 in Ohio. *J Comp Eff Res*. 2021;10(4):281-4.
25. Chen J, Vullikanti A, Hoops S, Mortveit H, Lewis B, Venkatramanan S, et al. Medical costs of keeping the US economy open during COVID-19. *Sci Rep*. 2020;10(1):18422.
26. Chen J, Vullikanti A, Santos J, Venkatramanan S, Hoops S, Mortveit H, et al. Epidemiological and Economic Impact of COVID-19 in the US. *medRxiv*. 2020.
27. Thom H, Walker J, Vickerman P, Hollingworth W. Exploratory comparison of Healthcare costs and benefits of the UK's Covid-19 response with four European countries. *Eur J Public Health*. 2021;31(3):619-24.
28. Gandjour A. The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany. *Q Rev Econ Finance*. 2020.
29. Barnett-Howell Z, Watson OJ, Mobarak AM. The benefits and costs of social distancing in high- and low-income countries. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2021;115(7):807-19.
30. Zala D, Mosweu I, Critchlow S, Romeo R, McCrone P. Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom. *Value Health*. 2020;23(11):1432-7.
31. Miles DK, Heald AH, Stedman M. How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out? *Int J Clin Pract*. 2021;75(7):e14191.
32. Miles DK, Stedman M, Heald AH. "Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom. *Int J Clin Pract*. 2021;75(3):e13674.

33. Keogh-Brown MR, Jensen HT, Edmunds WJ, Smith RD. The impact of Covid-19, associated behaviours and policies on the UK economy: A computable general equilibrium model. *SSM Popul Health*. 2020;12:100651.
34. Shlomai A, Leshno A, Sklan EH, Leshno M. Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis. *Value Health*. 2021;24(5):607-14.
35. Kouidere A, Youssoufi LE, Ferjouchia H, Balatif O, Rachik M. Optimal Control of Mathematical modeling of the spread of the COVID-19 pandemic with highlighting the negative impact of quarantine on diabetics people with Cost-effectiveness. *Chaos Solitons Fractals*. 2021;145:110777.
36. Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. *Ann Intern Med*. 2021;174(6):803-10.
37. Currie J, Adamson J, Bowden B, Woolls J, Jones R, Healy B, et al. Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: a cost-minimisation analysis. *BMJ Open*. 2020;10(8):e038017.
38. Neilan AM, Losina E, Bangs AC, Flanagan C, Panella C, Eskibozkurt GE, et al. Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. *Clin Infect Dis*. 2021;73(9):e2908-e17.
39. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis. *Ann Intern Med*. 2021;174(4):501-10.
40. Baggett TP, Scott JA, Le MH, Shebl FM, Panella C, Losina E, et al. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. *JAMA Netw Open*. 2020;3(12):e2028195.
41. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. *JAMA Netw Open*. 2020;3(7):e2016818.
42. Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis. *Health Technol Assess*. 2021;25(21):1-68.
43. Risko N, Werner K, Offorjebe OA, Vecino-Ortiz AI, Wallis LA, Razzak J. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. *PLOS ONE*. 2020;15(10):e0240503.
44. Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. *J Allergy Clin Immunol Pract*. 2021;9(7):2658-68.e3.
45. Bartsch SM, O'Shea KJ, Wedlock PT, Strych U, Ferguson MC, Bottazzi ME, et al. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. *Am J Prev Med*. 2021;60(5):605-13.
46. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. *Vaccine*. 2021;39(7):1157-64.

47. Vernaz N, Agoritsas T, Calmy A, Gayet-Ageron A, Gold G, Perrier A, et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. *Swiss Med Wkly*. 2020;150:w20446.
48. Lee BY, Bartsch SM, Ferguson MC, Wedlock PT, O'Shea KJ, Siegmund SS, et al. The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *PLoS Comput Biol*. 2021;17(1):e1008470.
49. Águas R, Mahdi A, Shretta R, Horby P, Landray M, White L, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. *Nature Communications*. 2021;12(1):915.
50. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. *Adv Ther*. 2021;38(4):1811-31.
51. Ebigbo A, Römmele C, Bartenschlager C, Temizel S, Kling E, Brunner J, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. *Endoscopy*. 2021;53(2):156-61.
52. Losina E, Leifer V, Millham L, Panella C, Hyle EP, Mohareb AM, et al. College Campuses and COVID-19 Mitigation: Clinical and Economic Value. *Ann Intern Med*. 2021;174(4):472-83.
53. Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. *Lancet Infect Dis*. 2021;21(7):962-74.
54. Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore YPA, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. *Lancet Public Health*. 2021;6(3):e184-e91.
55. Gandjour A. How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. *Appl Health Econ Health Policy*. 2021;19(2):181-90.
56. Fan CY, Fann JC, Yang MC, Lin TY, Chen HH, Liu JT, et al. Estimating global burden of COVID-19 with disability-adjusted life years and value of statistical life metrics. *J Formos Med Assoc*. 2021;120 Suppl 1:S106-s17.
57. Vardavas C, Nikitara K, Zisis K, Athanasakis K, Phalkey R, Leonardi-Bee J, et al. Cost-effectiveness of emergency preparedness measures in response to infectious respiratory disease outbreaks: a systematic review and econometric analysis. *BMJ Open*. 2021;11(4):e045113.
58. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *International Journal of Surgery*. 2020;78:185-93.
59. Vandepitte S, Alleman T, Nopens I, Baetens J, Coenen S, De Smedt D. Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review. *Value in Health*. 2021;24(11):1551-69.
60. Juneau C-E, Pueyo T, Bell M, Gee G, Collazzo P, Potvin L. Evidence-Based, Cost-Effective Interventions To Suppress The COVID-19 Pandemic: A Systematic Review. *medRxiv*. 2020:2020.04.20.20054726.

TABLES AND FIGURES

Figure 1. PRISMA flow chart of the search strategy




Table 1. Overview of included studies evaluating the economic impact of COVID-19 pandemic in EU/EEA/UK and OECD countries (n=10)

Study/Publication Year	Country	Population	Study design	Economic evaluation method	Costs calculation	Perspective	Funding
Degeling et al, 2021 (15)	Australia	65 415 cases - 2020 Australian incident breast cancer, colorectal cancer, lung cancer, and melanoma patient populations	Modeling	Cost of illness analysis	Direct medical costs	Public healthcare payer	No funding
Czernichow et al, 2021 (16)	European countries	720 □ 547 hospitalizations	Modeling	Cost of illness analysis	Direct medical costs	Healthcare system	Yes
Bain et al, 2021 (17)	European countries	720 □ 547 hospitalizations	Modeling	Cost of illness analysis	Direct medical costs	Healthcare system	Yes
Mallow et al, 2021 (24)	USA/Ohio	6 429 Ohioans deaths	Retrospective cohort study	Partial economic evaluation	Not clearly specified	Not clearly specified	No funding
Nurchis et al, 2020 (18)	Italy	Italian population	Observational study	Cost of illness analysis	Indirect costs	Societal	No funding
Bartsch et al, 2020 (19)	USA	USA population	Simulation	Cost of illness analysis	Direct medical costs	1) Health system, 2) third-payer	Yes
Lee et al, 2020 (20)	Korea	145 hospitalized children with COVID-19	Retrospective cohort study	Cost of illness analysis	Direct medical costs	Third payer	Not clearly specified
Kirigia et al, 2020 (21)	UK	UK population	Retrospective cohort study	Economic impact analysis/Cost of illness	Indirect costs (using human capital approach)	Societal	No funding
Gedik et al, 2020 (23)	Turkey	459 patients - 393 clinical patients 66 intensive care unit patients	Retrospective cohort study	Cost analysis	Direct medical costs	Third payer	Not clearly specified
DiFusco et al, 2021 (22)	USA	173 942 hospitalized COVID-19 patients	Retrospective cohort study	Cost of illness analysis	Direct medical costs	Healthcare system	Yes

USA: United States of America, UK: United Kingdom

Table 2. Econometric outcomes of studies evaluating the economic impact of COVID-19 in the EU/EEA/UK and OECD countries (n=10)

Study/ Publication Year	Time horizon	Discounting	Modeling - uncertainty assessment	Economic evaluation outcomes, €, 2021	Uncertainty assessment results, €, 2021
Degeling et al, 2021	5 and 10-year	Not applied	Inverse stage/shift model Uncertainty assessment Not applied	Incremental cost – 3 month delay Breast cancer: 1 09 million € Coloecteral cancer: 227 082 € Lung cancer: - Melanoma: 5 02 million € Incremental cost – 6 month delay Breast cancer: 4 25 million € Coloecteral cancer: 895 070 € Lung cancer: - Melanoma: 20 1 million €	Not applied
Czernichow et al, 2021	6 months	Not applied	Healthcare cost model Uncertainty assessment Not applied	Costs per average hospital admission - By BMI - Average (weighted for all countries) 2) BMI <25: 16 173 € 3) BMI 25–29.9: 17 389 € - 24 324 € 4) BMI 30–34.9: 24 324 € 5) BMI 35–39.9: 25 409 € 6) BMI ≥40: 31 652 € Total direct costs of secondary care of COVID-19 – by BMI 1) Totally (720 547 hosp. people): 14 2 billion € 2) BMI <25 (211 407 hosp. people): 3 37 billion € 3) BMI 25–29.9 (259 764 people): 4 5 billion € 4) BMI 30–34.9 (174 278 hosp. people): 4 2 billion € 5) BMI 35–39.9 (54 673 hosp. people): 1 38 billion € 6) BMI ≥40 (20 424 hosp. people): 664 million €	Not applied
Bain et al, 2021	6 months	Not applied	Healthcare cost model Uncertainty assessment Not applied	Total direct costs of secondary care of COVID-19 1) Totally (720 547 hosp. cases): 14 2 billion € 2) With diabetes (95 255 hosp. cases): 10 8 billion € 3) Without diabetes (625 292 hosp. cases): 3 34 billion € Total direct costs of secondary care of COVID-19 – per diabetes type 1) <u>Type 1</u> a) Good glycaemic control (2 656 hosp. cases): 78 6 million €	Lower and upper bound estimations The range for total direct secondary care costs is 11 3 billion € - 21 8 billion €

				<p>b) Poor glycaemic control (6 869 hosp. cases): 400 4 million €</p> <p>2) <u>Type 2</u></p> <p>a) Good glycaemic control (54 028 hosp. cases): 1 367 billion</p> <p>b) Poor glycaemic control (31 701 hosp. cases): 1 498 billion</p>	
Mallow et al, 2021	From the beginning of Covid-19 infection as of 30 November 2020 in Ohio	Not applied	<p>Not applied</p> <p>Uncertainty assessment</p> <p>Not applied</p>	<p>Value of statistical life</p> <p>Low: 15 492 826 678 €</p> <p>¹Base: 13 814 246 372 €</p> <p>High: 17 979 395 429 €</p> <p>Value of statistical life, per sex</p> <p>Male: 7 443 681 213 €</p> <p>Female: 6 351 426 503 €</p> <p>Unknown: 19 138 654 €</p> <p>Value of statistical life, per age</p> <p>Less than 60 y: 3 092 373 227 €</p> <p>60 y or older: 10 720 747 342 €</p> <p>Unknown: N/A</p>	Not applied
Nurchis et al, 2020	Approximately 3 months	3% for the individual future annual wages	<p>Not applied</p> <p>Uncertainty assessment</p> <p>Not applied</p>	<p>Temporary productivity loss cost</p> <p>Totally (110 868 cases): 114 120 531 € or 1 029 € per case</p> <p>20-29 y (10 369 cases): 9 191 575 €</p> <p>30-39y (14 858 cases): 15 088 029 €</p> <p>40-49y (25 420 cases): 25 813 548 €</p> <p>50-59y (35 068 cases): 37 284 537 €</p> <p>60-69y (25 153 cases): 26 742 841 €</p> <p>Permanent productivity loss cost</p> <p>Totally (3 926 deaths): 333 063 591 € or 84 836 € per death</p> <p>20-29 y (8 deaths): 1 755 371 €</p> <p>30-39y (49 deaths): 10 854 412 €</p> <p>40-49y (224 deaths): 40 636 472 €</p> <p>50-59y (918 deaths): 122 559 274 €</p> <p>60-69y (227 deaths): 157 258 062 €</p>	Not applied
Bartsch et al, 2020	Incurred during the course of the infection and postdischarge for one year	3% for costs	<p>Monte Carlo simulation</p> <p>Uncertainty assessment:</p> <p>Scenarios and sensitivity analyses by</p>	<p>Direct medical cost, per case</p> <p>1) A person with symptomatic infection, i) including only costs during the course of the infection, ii) one year after postdischarge:</p> <p>Median: 2 418 € (95% UI 2 282 € - 2 545 €)</p> <p>Median: 3 192 € (95% UI 3 017 € - 3 336 €)</p> <p>2) A person with only mild symptoms by age group, including only costs during the course of the infection:</p> <p>a) 0-17 y - Median: 72 € (95% UI 48 € - 98 €)</p> <p>b) 18-64 y - Median: 45 € (95% UI 43 € - 53 €)</p>	<p>20% attack (infection) rate:</p> <p>Decreasing post-discharge costs by 50 percent would lower that amount to a median of 149 8 billion € [95% UI: 142 0 €, 158 7 billion €].</p> <p>Decreasing the currently reported values for the probability of death by a relative 95 percent had little impact on direct medical costs - median: 170 7 billion € [95% UI:</p>

			<p>varying several key parameters to determine their impact on our results</p>	<p>c) 65 y or older Median: 76 € (95% UI 71 € - 82 €)</p> <p>3) A person with symptomatic infection requiring hospitalization, by age group - including only costs during the course of the infection:</p> <p>a) 0-17 y - Median: 9 027 € (95% UI 7 203 – 10 991 €)</p> <p>b) 18-44 y - Median: 10 429 € (95% UI 9 141 € - 11 707 €)</p> <p>c) 45-64 y - Median: 12 661 € (95% UI 11 451 € - 13 943 €)</p> <p>d) 65-84 y - Median: 12 661 € (95% UI 11 261 € - 12 340 €)</p> <p>e) 85 y or older - Median: 9 451 € (95% UI 8 807 € - 10 193 €)</p> <p>Direct medical costs,</p> <p>i) incurred during the course of the infection,</p> <p>ii) post discharge (with current reported values) - Attack (infection) rates in US</p> <p>1) 20% infection rate: 129 8 billion (95% UI 122 7 – 137 5), ii) 170 3 billion (95% 160 7 –181)</p> <p>2) 50% infection rate: i) 324 6 billion (95% UI 306 7 – 344 2), ii) 426 3 billion (95% 403 1 –453 3)</p> <p>3) 80% infection rate: i) 519 4 billion (95% UI 489 05 – 550), ii) 682 6 billion (95% 642 8 – 724 05)</p>	<p>161 06 billion €, 180 4 €].</p> <p>50% attack (infection) rate: Reducing the post-discharge costs by 50 percent decreased the median direct medical costs to 375 2 billion € [95% UI: 355 billion €, 398 1 billion €].</p> <p>80% attack (infection) rate: If post-discharge costs were 50 percent lower, median costs would be reduced from 682 7 billion € to 600 5 billion € [95% UI: 565 8 billion €, 637 4 billion €]. The decrease of the probability of severe disease leads to decreased costs by a relative 49 7%, to 261 2 billion €. Decreasing the reported value for the probability of death by a relative 95% had no impact on cost when costs that might be incurred after discharge were included[median: 682 7 billion €; 95% UI: 646 2 billion €, 722 2 billion €]</p>
Lee et al, 2020	2 months	Not applied	<p>Not applied</p> <p>Uncertainty assessment Not applied</p>	<p>Medical costs, per age-group and mean hospitalization days</p> <p>a) Totally (145 patients): 252 389 € for 10.38 days (95% UI 8 38 – 12 38 hospitalization days) Per patient: 1.740 6 €</p> <p>b) 0-5y (57 patients): 33 927 € for 4.63 days (95% UI 2 99 – 6 27 hospitalization days) Per patient: 594 8 €</p> <p>c) 6-10y (15 patients): 30 786 € for 10.87 days (95% UI 6 85 – 14 89 hospitalization days) Per patient: 2.051 8 €</p> <p>d) 11-15y (19 patients): 30 937 € for 14.88 days (95% UI 8 86 – 14 72 hospitalization days) Per patient: 1.628 05 €</p>	<p>Not applied</p>

				e) 16-19y (54 patients): 156 738 € for 15.81 days (95% UI 11 42 – 20 20 hospitalization days) Per patient: 2.902 7 €	
Kirigia et al, 2020	Onset and as of July 2020	3%, 5% and 10%	Not applied Uncertainty assessment Not applied	Present value of human lives lost, at 3%, 5% and 10% discount rate 1) Totally (43 906 lives lost): 7 849 137 714 €, 6 929 149 668 €, 5 419 985 376 € 2) 0-9y: - 3) 10-19y: 10 034 444 €, 6 929 149 668 €, 3 486 414 € 4) 20-29y: 61 632 496 €, 42 586 289 €, 22 600 723 € 5) 30-39y: 462 939 584 €, 113 659 147 €, 62 493 943 € 6) 40-49y: 462 939 584 €, 348 997 800 €, 202 697 939 € 7) 50-59y: 1 272 389 584 €, 1 016 620 912 €, 641 312 072 € 8) 60-69y: 1 950 013 557 €, 1 669 784 612 €, 1 188 059 923 € 9) 70-79y: 2 140 118 842 €, 1 987 634 724 €, 1 672 314 872 € 10) 80 & older: 1 793 826 428 €, 1 743 147 320 €, 1 627 019 486 €	Not applied
Gedik et al, 2020	Approx. 2 months	Not applied	Not applied Uncertainty assessment Not applied	Mean cost, per patient Clinical patients: 700 26 € (SD 529 96 €) for 8.97 (SD 4 64) mean hospitalization days One-day hospitalization: 82 05 € (SD 61 58 €) Intensive care unit patients: 2 322 € (SD 1 864 €) for mean hospitalization days of 14 74 (SD 13.19) One-day hospitalization: 188 01 € (SD 75 02 €)	Not applied
DiFusco et al, 2021	8 months	Not applied	Not applied Uncertainty assessment: A sensitivity analysis using the U07.1 ICD-10 code in the primary position only	Direct costs (hospital costs) 1) Overall study population (n= 173 942) for 8.3 mean LOS: 19 513 € (mean), 32 545 € (SD) 2) Without ICU or IMV (n= 128 063) for 6.1 mean LOS: 11 376 € (mean), 13 302 € (SD) 3) With ICU but without IMV (n= 16 496) for 9.6 mean LOS: 20 400 € (mean), 21 850 € (SD) 4) Without ICU but with IMV (n= 7 751) for 12.1 mean LOS: 33 171 € (mean), 40 810 € (SD) 5) With ICU and IMV (n= 21 632) for 18.6 mean LOS: 62 139 € (mean), 64 821 € (SD)	The sensitivity analysis of hospitalized COVID-19 patients identified 106 801 patients, representing 61.4% of the hospitalized COVID-19 patients included in the main analyses. Mean hospital charges: mean [SD]: 61 484 € - 108 472 € - consistent with the main analyses but slightly lower Mean hospital costs: mean [SD]: 16 834 € - 28 588 € - slightly lower than in the main analyses

			<p>Direct costs (hospital charges)</p> <p>1) Overall study population (n= 173 942) for 8.3 mean LOS: 72 132 € (mean), 126 212 € (SD)</p> <p>2) Without ICU or IMV (n= 128 063) for 6.1 mean LOS: 40 157 € (mean), 43 931 € (SD)</p> <p>3) With ICU but without IMV (n= 16 496) for 9.6 mean LOS: 75 879 € (mean), 79 852 € (SD)</p> <p>4) Without ICU but with IMV (n= 7 751) for 12.1 mean LOS: 125 887 € (mean), 156 833 € (SD)</p> <p>5) With ICU and IMV (n= 21 632) for 18.6 mean LOS: 239 308 € (mean), 260 664 € (SD)</p>	
--	--	--	---	--

BMI: Body mass index, US: United States, y: years, n: number, N/A: Not applicable SD: Standard deviation, ICU: Intensive Care Unit, IMV: Invasive mechanical ventilation, LOS: Length of stay
 1 The base case is the best estimate of YPLL and associated value of statistical life years lost. The low and high represent the estimated range

Table 3. Study characteristics of studies assessing the cost-effectiveness of strategies for mitigating the COVID-19 pandemic (n=31)

Study/ Publication Year,	Funding	Country* and Population	Study design	Perspective	Intervention/strategy
Pandey et al, 2021 (54)	Yes	USA 328 2 million (US population)	Modeling and simulation	Societal	1. Daily test plus 1-week isolation, 2. Daily test plus 2-week isolation, 3. Test every 7 days plus 1-week isolation, 4. Test every 7 days plus 2-week isolation, 5. Test every 14 days plus 1-week isolation, 6. Test every 14 days plus 2-week isolation, 7. Test every 28 days plus 1-week isolation, 8. Test every 28 days plus 2-week isolation
Lee et al, 2021 (48)	Yes	USA 327 167 434 persons (US population)	Modeling and simulation	Third payer and societal perspective	Starting treatment (medication of vaccination)
Kouidere et al, 2021 (35)	Not mentioned	Worldwide Diabetics	Modeling and simulation	Not clearly mentioned	1. Quarantine, 2. Sensitization and prevention, 3. Awareness Program and Quarantine
Bastos et al, 2021 (39)	Yes	Worldwide 7 169 Participants (inpatients and outpatients)	Systematic review and meta-analysis	Societal	1. Saliva sampling (collection of specimens by saliva) VS 2. nasopharyngeal swab (collection of specimens by nasopharyngeal swab)
Risko et al, 2020 (43)	No funding	Low- and middle-income countries ¹ 166 689 862 simulated healthcare worker cases	Modeling and simulation	Societal	1. Unmitigated (low PPE), 2. Unmitigated (full PPE), 3. Mitigated (low PPE), 4. Mitigated (full PPE), 5. Suppressed (low PPE), 6. Suppressed (full PPE)
Stevenson et al, 2021 (42)	Yes	UK Patients admitted to hospital	Modeling and simulation	Healthcare system	30 testing strategies - All of these used the base-case values for the laboratory-based test and the POCT 1. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours 2. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test

					<p>result of 35.9 hours, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours</p> <p>3. Test on admission to the hospital with SARS-CoV-2 POCTs with a time to test result of 30 minutes, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 POCTs and with a time to test result of 30 minutes, and routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay test with SARS-CoV-2 POCTs with a time to test result of 30 minutes</p> <p>4. Test on admission to the hospital with SARS-CoV-2 POCTs with a time to test result of 30 minutes, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 POCTs and with a time to test result of 30 minutes, and routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay test with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours</p> <p>5. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 POCTs with a time to test result of 30 minutes</p> <p>6. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and weekly asymptomatic staff testing with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours</p> <p>7. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and weekly asymptomatic staff testing with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours</p> <p>8. Test on admission to the hospital with SARS-CoV-2 POCTs with a time to test result of 30 minutes, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 POCTs with a time to test result of 30 minutes, routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 POCTs with a time to test result of 30 minutes, and weekly asymptomatic staff testing with SARS-CoV-2 POCTs with a time to test result of 30 minutes</p> <p>9. Test on admission to the hospital with SARS-CoV-2 POCTs with a time to test result of 30 minutes, retest those with clinical symptoms suggestive of COVID-19 but with a negative</p>
--	--	--	--	--	--

					<p>SARS-CoV-2 test with SARS-CoV-2 POCTs with a time to test result of 30 minutes, routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, and weekly asymptomatic staff testing with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours</p> <p>10. Test on admission to the hospital with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, retest those with clinical symptoms suggestive of COVID-19 but with a negative SARS-CoV-2 test with SARS-CoV-2 laboratory-based tests with a time to test result of 35.9 hours, routine retesting following admission to hospital in a non-SARS-CoV-2 infection-suspected bay with SARS-CoV-2 POCTs with a time to test result of 30 minutes, and weekly asymptomatic staff testing with SARS-CoV-2 POCTs with a time to test result of 30 minutes</p> <p>11. As strategy 2 but using a time to test result of 24 hours for the laboratory-based test</p> <p>12. As strategy 2 but using a time to test result of 6 hours for the laboratory-based test</p> <p>13. As strategy 3 but using the acceptable TPP for POCTs</p> <p>14. As strategy 3 but using data from currently available POCTs</p> <p>15. As strategy 14 but using a time to test result of 8 hours</p> <p>16. As strategy 4 but using the acceptable TPP for POCTs</p> <p>17. As strategy 4 but using data from currently available POCTs,</p> <p>18. As strategy 5 but using a time to test result of 24 hours for the laboratory-based test</p> <p>19. As strategy 5 but using a time to test result of 6 hours for the laboratory-based test</p> <p>20. As strategy 6 but using a time to test result of 24 hours for the laboratory-based test</p> <p>21. As strategy 6 but using a time to test result of 6 hours for the laboratory-based test</p> <p>22. As strategy 7 but using a time to test result of 24 hours for the laboratory-based test</p> <p>23. As strategy 7 but using a time to test result of 6 hours for the laboratory-based test</p> <p>24. As strategy 8 but using the acceptable TPP for POCTs</p> <p>25. As strategy 8 but using data from currently available POCTs</p> <p>26. As strategy 25 but using a time to test result of 8 hours</p> <p>27. As strategy 9 but using the acceptable TPP for POCTs</p> <p>28. As strategy 9 but using data from currently available POCTs</p> <p>29. As strategy 10 but using a time to test result of 24 hours for the laboratory-based test</p> <p>30. As strategy 10 but using a time to test result of 6 hours for the laboratory-based test</p>
Shlomai et al, 2020 (34)	No funding	Israel Simulated population of Israel (9 million population)	Modeling and simulation	Societal	<p>1. Isolation – complete isolation of infected individuals or individuals at high exposure risk in a dedicated facility, 2. National lockdown of the susceptible population - national lockdown, isolation of all infected individuals, and a 14-day isolation period for the high exposure risk group</p>
Keogh-Brown et al,	Yes	UK population	Modeling and simulation	Societal	<p>1. No action is taken to mitigate the virus spread VS</p> <p>2. Mitigation policy,</p>

2020 (33)		based on UN population projections			3. Suppression policy
Águas et al, 2021 (49)	Yes	UK 300 000 Hospitalised COVID-19 patients	Modeling and simulation	Healthcare system	1. Dexamethasone treatment VS 2. No Dexamethasone treatment
Miles et al, 2020 (32)	Not clearly specified	UK Over 5 million citizens	Modeling	Societal	Lockdown policy
Shaker et al, 2021 (44)	Yes	USA Individual and 300 000 000 simulated persons	Simulation	1) Healthcare and 2) Societal	1. Universal COVID-19 vaccination VS 2. Risk-stratified vaccination ²
Miles et al, 2021 (31)	Not clearly specified	UK 56 000 000 citizens	Modeling and simulation	Not clearly specified, however, societal could be ideal to mention	Physical restriction scenarios: 1. Base—no transition (0 wk High then 0 wk Medium then 26 wk Low), 2. I - Short transition (8 wk Medium then 18 wk Low), 3. II - Long transition (4 wk High then 12 wk stepped reduction - Medium), 4. III -Keep at high for 26 wk
Zala et al, 2020 (30)	No funding	UK UK population	Simulation	Societal	Suppression policies: 1) Suppression 1 (triggered “on” when there are 100 ICU cases in a week and “off” when weekly cases halve to 50 cases) VS unmitigated, 2) Suppression 1 (triggered “on” when there are 100 ICU cases in a week and “off” when weekly cases halve to 50 cases) VS mitigated, 3) Suppression 2 (triggered “on” when there are 400 ICU cases in a week and “off” when weekly cases halve to 200 cases) VS unmitigated, 4) Suppression 2 (triggered “on” when there are 400 ICU cases in a week and “off” when weekly cases halve to 200 cases) VS mitigated
Sheinson et al, 2021 (50)	Yes	USA Modeled population of hospitalized	Modeling	1) Healthcare, 2) Societal, 3) Payer	Treatment in the hospital with COVID-19 treatments VS Best supportive care (BSC)

		patients with COVID-19			
Neilan et al, 2020 (38)	Yes	USA Initial distribution of COVID-19 disease severity by age which has been derived from the Massachusetts Census and Department of Public Health	Modeling and simulation	Healthcare system	Testing strategies: 1) hospitalized: PCR testing only for patients with severe/critical symptoms warranting hospitalization, 2) symptomatic: PCR for any COVID-19-consistent symptoms, with self-isolation if positive, 3) symptomatic + asymptomatic once: symptomatic and 1-time PCR for the entire population, 4) symptomatic + asymptomatic monthly: symptomatic with monthly retesting for the entire population
Baggett et al, 2020 (40)	Yes	USA Modeled cohort of 2258 adults residing in homeless shelters in Boston, Massachusetts	Modeling and simulation	Healthcare system	1) No intervention VS 2) Symptom screening, PCR, and hospital, 3) Symptom screening, PCR, and ACS, 4) Universal PCR testing and hospital, 5) Universal PCR and ACS, 6) Universal PCR and temporary housing, 7) Hybrid hospital (symptom screening, PCR, and hospital strategy and adds shelter-based universal PCR testing every 2 weeks for those without symptoms), 8) Hybrid ACS (symptom screening, PCR, and ACS strategy and adds shelter-based universal PCR testing every 2 weeks for those without symptoms)
Currie et al, 2020 (37)	No funding	Wales 192 suspected COVID-19 cases in community and standard hospital testing practices	Retrospective cohort study	Healthcare system	1) Community testing by swabbing VS 2) Hospital standard testing
Sandmann et al, 2021 (53)	Yes	UK UK population	Modeling and simulation	Healthcare system and society	Vaccination alongside physical distancing measures 1) No vaccination VS 2) Vaccination (worst case), 3) Vaccination (best case)

Barnett-Howell et al, 2021 (29)	Yes	High and low income countries (including the UK, US) Susceptible modeled population at the start of the pandemic	Simulation	Not clearly specified	Physical distancing strategies: 1) Unmitigated spread of COVID-19, where the virus progresses through each country at a high level of infectivity, 2) Individual distancing policy, similar to the case of a country like Sweden where workplaces, schools and restaurants mostly remain open but large gatherings are discouraged, reducing infectivity by 15%, 3) Broad physical distancing policy, equivalent to the closure of schools and workplaces, that reduces infectivity by 35%, 4) Physical distancing+, which is an even more intensive physical distancing policy with targeted stay-at-home orders, 5) Full lockdown policies designed to entirely suppress physical contact, closing transit and stay-at-home orders for the entire population, reducing infectivity by 60%
Gandjour et al, 2020 (28)	No funding	Germany German population	Modeling	Societal	1) No intervention, VS 2) Shutdown in scenario of "Flattening the curve", 3) Shutdown in scenario of "Squashing the curve", 4) ICU capacity exceeded by 50 %, 5) ICU capacity exceeded by 100 %, 6) ICU capacity exceeded by 200 %, 7) ICU capacity exceeded by 300 %
Gandjour et al, 2021 (55)	No funding	Germany German population	Modeling	Societal	ICU bed provision
Bartsch et al, 2021 (45)	Yes	USA U.S. population	Modeling and simulation	a) third-party payer, b) societal	1) Vaccine that reduces severe disease, 2) Vaccine that prevents infection, 5% have already been infected, 3) Vaccine that prevents infection, 25% have already been infected, 4) Vaccine that prevents infection, 50% have already been infected
Thom et al, 2021 (27)	Yes	European countries (UK, Ireland, Germany, Spain and Sweden) Population of these European countries	Modeling	Health system	1) Scenario A (base case) - Government response mitigation under $R_0=2.7$, 2) Scenario B - Government response mitigation under $R_0=1.6$, 3) Scenario C - Government response mitigation under $R_0=3.9$, 4) Scenario: All GDP reduction due to response
Kohli et al,	Yes	USA	Modeling and	Healthcare	1) No vaccine VS

2021 (46)		Every adult (18 years and older) in the US	simulation	system	2) COVID-19 vaccine
Chen et al, 2020 (25)	Yes	USA US population	Modeling and simulation	Healthcare system	1) Stay-home for 0 days (unmitigated scenario) VS 2) Stay-home for 30 days, with VHI & SHI 60% compliance rate, 3) Stay-home for 30 days, with VHI & SHI 70% compliance rate, 4) Stay-home for 30 days, with VHI & SHI 80% compliance rate, 5) Stay-home for 30 days, with VHI & SHI 90% compliance rate, 6) Stay-home for 45 days, with VHI & SHI 60% compliance rate, 7) Stay-home for 45 days, with VHI & SHI 70% compliance rate, 8) Stay-home for 45 days, with VHI & SHI 80% compliance rate, 9) Stay-home for 45 days, with VHI & SHI 90% compliance rate, 10) Stay-home for 60 days, with VHI & SHI 60% compliance rate, 11) Stay-home for 60 days, with VHI & SHI 70% compliance rate, 12) Stay-home for 60 days, with VHI & SHI 80% compliance rate, 13) Stay-home for 60 days, with VHI & SHI 90% compliance rate
Losina et al, 2020 (52)	Yes	USA 105 000 cohort size	Simulation	Modified societal	No intervention VS Isolation intervention, masks wearing and laboratory testing/self-screen strategies a) Residence-based isolation, incl. self-screen, b) Designated space for isolation, incl. self-screen, c) Designated spaces for isolation + 1-time laboratory testing, d) Designated spaces for isolation + routine laboratory testing every 14 days, e) Designated spaces for isolation + routine laboratory testing every 7 days, f) Designated spaces for isolation + routine laboratory testing every 3 days
Chen et al, 2020 (26)	Yes	USA US population	Simulation	Societal	1) No non-pharmaceutical interventions applied VS 2) Stay-home for 30 days, with 60%-70%-80%-90% compliance rate, 3) Stay-home for 45 days, with 60%-70%-80%-90% compliance rate, 4) Stay-home for 60 days, with 60%-70%-80%-90% compliance rate
Vernaz et al, 2020 (47)	No funding	Switzerland 840 Hospitalized patients with a SARS-CoV-2 infection in COVID-19 wards	Retrospective cohort study	Healthcare system	1) Standard of Care (SoC) VS 2) 400 mg of lopinavir/ritonavir twice daily for 5 days under the age of 75 years and 400 mg of lopinavir/ritonavir in the morning and 200 mg of lopinavir/ritonavir in the evening for patients over 75, 3) A single dose of 800 mg of hydroxychloroquine, 4) Lopinavir/ritonavir and hydroxychloroquine dual therapy at the same dosages. Lopinavir/ritonavir was first prescribed on 5 March 2020, and hydroxychloroquine alone or combined with lopinavir/ritonavir on 20 March 2020
Ebigbo et al, 2021 (51)	Not mentioned/Not specified	Germany Simulation of 10 000 asymptomatic patients, 20	Simulation	Societal	1) No routine pre-endoscopy virus test; use of surgical masks, goggles, gloves, and apron for all procedures, 2) No routine pre-endoscopy virus test; additional use of FFP-2 masks and water-resistant gowns for all procedures, 3) Decentralized POC antigen test; use of surgical masks, goggles, gloves, and apron for all procedures, 4) Decentralized POC antigen test; additional use of FFP-2 and water-resistant gowns for all procedures irrespective of test result, 5) Centralized

		full-time HCWs with two FFP-2 masks per day			laboratory-based rapid PCR test; use of surgical masks, goggles, gloves, and apron for all procedures, 6) Centralized laboratory-based rapid PCR test; additional use of FFP-2 and water-resistant gowns for all procedures irrespective of test result, 7) Centralized laboratory-based standard PCR test; use of surgical masks, goggles, gloves, and apron for all procedures, 8) Centralized laboratory-based standard PCR test; additional use of FFP-2 and water-resistant gowns for all procedures irrespective of test result
Paltiel et al, 2020 (41)	Yes	USA 4 990 students without SARS-CoV-2 infection and 10 students with undetected asymptomatic cases of SARS-CoV-2	Modeling	Societal	1) Symptom-based screening, with no test sensitivity, 2) Weekly screening, with 70% test sensitivity, 3) Weekly screening, with 80% test sensitivity, 4) Weekly screening, with 90% test sensitivity, 5) Every 3 days screening,, with 70% test sensitivity, 6) Every 3 days screening,, with 80% test sensitivity, 7) Every 3 days screening, with 90% test sensitivity, 8) Every 2 days screening, with 70% test sensitivity, 9) Every 2 days screening, with 80% test sensitivity, 10) Every 2 days screening, with 90% test sensitivity, 11) Daily screening, with 70% test sensitivity, 12) Daily screening, with 80% test sensitivity, 13) Daily screening, with 70% test sensitivity
Paltiel et al, 2021 (36)	Yes	USA U.S. population	Modeling	Societal	1) No home-based SARS-CoV-2 antigen testing VS 2) home-based SARS-CoV-2 antigen testing

USA: United States of America, US: United States, PPE: Personal Protective Equipment, UK: United Kingdom, HWC: Home Healthcare Worker, VHI: Voluntary Home Isolation, SHI: Stay Home Isolation, GDP: Gross Domestic Product, PPE: Personal protective equipment, POCT: Point-of-care test, PCR: Polymerase Chain Reaction, ACS: Alternative Care Site, TPP: Target product profile, wk: weekLOS: Length of Stay, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, FFP-2: Filtering Facepiece 2

¹ Including countries in Europe

² based on history of anaphylaxis attributable to any trigger, where vaccination is deferred in patients with a history of self-reported anaphylaxis

Table 4. Economic evaluation outcomes concerning interventions and strategies to mitigate Covid-19 (n=31)

Study/ Publication Year	Economic evaluation method	Cost calculation	Time horizon	Discounting	Modeling	Uncertainty assessment method	Economic evaluation outcomes, €, 2021	Uncertainty assessment results
Pandey et al, 2021	Cost-effectiveness analysis (CEA)	Direct medical and indirect costs	5 months	Not applied	Stochastic transmission individual-based chain-binomial model	<p>1. transmission scenarios, with R_e ranging from 1.1 to 3 - by assuming a willingness to pay per YLL averted of US\$100 000 and determining the best testing strategy at a price of \$5 per test and a threshold test price at which the status-quo strategy outperforms all testing strategies considered</p> <p>2. Robustness assessment of structural features of the model -</p> <p>3. Visualizing individual simulation results and reporting the probability that the chosen strategy was suboptimal to one or more of the alternative strategies</p>	<p>Cost-effectiveness acceptability frontier</p> <p>A) Daily test plus 1-week isolation: -</p> <p>B) Daily test plus 2-week isolation: Optimal strategy in R_e of 2.5 & 3.0, assuming that each test costs US 3 97 € and assuming a societal WTP per YLL averted of 79 417 €. Optimal in testing threshold of 218 € and 318 €, respectively.</p> <p>C) Test every 7 days plus 1-week isolation: Optimal strategy in R_e of 1.5. 1.6, 1.7, 1.8, assuming that each test costs 3 97 € and assuming a societal willingness to pay per YLL averted of 79 417 €. Optimal in testing threshold of 258 €, 218 €, 338 €, 377 € respectively.</p> <p>D) Test every 7 days plus 2-week isolation: a) Optimal strategy in R_e of 2.2 - At the base case, with a price of 3.97 € per test and willingness to pay per YLL averted of 79 417 €, is optimal for prices under 318 € per test, b) Furthermore, optimal at all willingness to pay per YLL averted thresholds above 7 942 €</p> <p>E) Test every 14 days plus 1-week isolation: Assuming a test cost of 3 97 € and willingness to pay per YLL averted of 79 417 €, testing every 14 days with 1-week isolation is optimal for moderate transmission rates (R_e 1.3–1.4), and</p>	Under several assumptions, weekly testing combined with 2-week isolation remains the preferred strategy under high transmission scenarios. Specifically, weekly testing combined with 2-week isolation remains the preferred strategy under high transmission scenarios (R_e of 2.2) for larger population sizes, if individuals are assumed to resume testing 30 days after a positive test, when using QALYs to assess COVID-19 morbidity averted in addition to YLL averted, and even when the strategy options are extended to include 10-day in addition to 1-week and 2-week isolation periods

						<p>monthly testing with 1-week isolation is optimal for lower transmission scenarios</p> <p>F) Test every 14 days plus 2-week isolation: -</p> <p>G) Test every 28 days plus 1-week isolation:Optimal strategy in Re of 1.1 & 1.2, assuming that each test costs 3 97 € and assuming a societal willingness to pay per YLL averted of 79 417 €. Optimal in testing threshold of 60 € and 99 €, respectively.</p> <p>H) Test every 28 days plus 2-week isolation: -</p>	
Lee et al, 2021	Cost-utility analysis (CUA)	a) Direct medical costs for the third payer perspective , b) direct and indirect costs for the societal perspective	1 year	3% for costs	Stochastic compartment model	<p>Sensitivity analyses, by varying the proportion of the population receiving medication or vaccination, ranging from 25% to 75%</p> <p>ICER (cost/QALY) <u>Scenario of decreasing average infectious period by 0.5 days</u></p> <p>A) At R0 3.5 Cost-effective from the societal perspective: 2690.65 €/QALY, when treating 75% of symptomatic cases and treatment course costs 397.1 € Cost-effective from the third payer perspective: ICER was ≤6 267 €/QALY saved, when at least 50% of all cases were treated</p> <p>B) At R0 2.0 Cost-effective from the third payer perspective: ICER was 42.1 € - 14,075 €/QALY saved, when treating 25% or 50% of symptomatic patients</p> <p>C) At R0 2.5 From third-payer perspective: Not cost-effective, treating symptomatic patients</p>	<p>Sensitivity analysis results are shown in the results section. Sensitivity analyses varied the proportion of the population receiving medication or vaccination, ranging from 25% to 75%, in order to show a more aggressive upper bound of potential coverage, when treatment started during the epidemic (after 5–15% of the population has been exposed), total treatment cost (397.1 € - 1985 €), and R0 (2.0–3.5)</p>

						<p>if treatment costs 397.1 €</p> <p><u>Scenario of decreasing average infectious period by 3.5 days</u></p> <p>At Ro 3.5 Cost-effective from the third-payer perspective: 2950 35 €/QALY, when treating 50 %of symptomatic cases and treatment course costs 397 1 €</p> <p>Cost-savings (Net) A) At Ro 3.5</p> <p><u>Scenario of decreasing average infectious period by 0.5 days</u> From the societal perspective: 90 13 billion €, when treating 75% of symptomatic cases and treatment course costs 397 1 €</p> <p><u>Scenario of decreasing average infectious period by 2 days</u> From the societal perspective: 432 19 billion €, when treating 25-75% of symptomatic cases and treatment course costs 397 1 € - in case of treating all infected the savings are 174 24 billion €</p> <p>From the third-payer perspective: 1 59 billion €, when treating 25-75% of symptomatic cases and treatment course costs 397 1 €</p> <p><u>Scenario of decreasing average infectious period by 3.5 days</u> From the societal perspective: 259 46 billion €, when treating 50% of symptomatic cases and treatment course costs 397 1 € - 339 27 billion € when</p>	
--	--	--	--	--	--	--	--

						<p>treating 75% of all infected patients</p> <p>B) At R0 2.0 <u>Scenario of decreasing average infectious period by 0.5 days</u></p> <p>From societal perspective: 60 05 billion €, when treating 25% or 50% of symptomatic patients From the third payer perspective: 3 01 billion €, when treating 25% or 50% of symptomatic patients</p> <p><u>Scenario of decreasing average infectious period by 3.5 days</u></p> <p>From societal perspective: 476 98 billion €, when treating 50% of symptomatic patients From the third payer perspective: 29 86 billion €, when treating 50% of symptomatic patients</p> <p>C) At R0 2.5 <u>Scenario of decreasing average infectious period by 0.5 days</u></p> <p>From societal perspective: 166 38 billion €, when treating 25% of symptomatic patients, if the treatment costs 397 1 € Even if treatment costs 1985 43 € and treating 50% of those patients, cost-savings of 35 66 € presented From third-payer perspective: Not cost-saving, if treatment costs 397 1 €</p> <p><u>Scenario of decreasing average infectious period by 2.0 days</u></p>	
--	--	--	--	--	--	--	--

							From third-payer perspective: > 7 39 billion €, when treating 50% of all infected patients if treatment costs 397 1 € From societal perspective: 154 32 billion €, when treating 50% of all infected patients, if the treatment costs 397 1 €	
Kouidere et al, 2021	Cost-effectiveness analysis (CEA)	Not clearly mentioned	Appr. 3,5 months	Not applied	Two mathematical models: i) for transmission of the COVID-19 disease between people, ii) for the dynamics of the diabetes population	Not applied	Mathematical ICER (cost per averted infection) Quarantine: 0.4774 Sensitization and prevention: -0.1962 Awareness program and quarantine: -0.6951 compared to sensitization and prevention Total cost per strategy Quarantine: 293 000 000 € Sensitization and prevention: 124 000 000 € Awareness program and quarantine: 75 500 000 €	Not applied
Bastos et al, 2021	Cost-effectiveness analysis (CEA)	Direct medical, non-medical and indirect costs	Not clearly specified	Not applied	Wilson method and generalized linear mixed models for the secondary analysis	Not applied	Incremental cost per additional SARS-CoV-2 infection identified - If the prevalence of SARS-CoV-2 in the sample population is: a) 0.01%, b) 0.1%, c) 1%, d) 10% Nasopharyngeal Swab compared to Saliva Sampling: a) 660 568 €, b) 64 270 €, c) 6 427 €, d) 6 425 € Cost-savings, if 100 000 persons are tested Saliva Sampling: 505 177 € (95% CI 371 217 €- 660 568 €) compared to Nasopharyngeal Swab	Not applied
Risko	Cost-	Direct	7,5	Not applied	Decision-	Bayesian multivariate	ICER (Cost per case averted)	Monte Carlo simulations showed

et al, 2020	effectiveness analysis (CEA) & Return on Investment analysis (ROI)	medical, non-medical, and indirect costs	months		analytic model & Susceptible-Infected-Removed (SIR) model	sensitivity analysis & Monte Carlo simulation (10,000 simulations)	<p>Purchasing and distribution of personal protective equipment to allow for adequate protection of all HCWs: 57.2 € (53.2 € to 61.2 €)</p> <p>ICER (Cost per death averted) Purchasing and distribution of personal protective equipment to allow for adequate protection of all HCWs: 4 159 € (3 861 to 4 556)</p> <p>Return on investment The investment of 7.6 billion € for purchasing PPE contributes to economic gains of 41.1 billion € (39.6 to 42.6)</p>	that the societal ROI from productivity gains is estimated to be 599.84 billion €, yielding the equivalent of a 7 932% ROI
Stevenson et al, 2021	Cost-utility analysis (CUA)	Direct medical costs	Appr. 6,5 months	3.5% per annum for health benefits. No discounting for costs.	Computer individual patient model	Sensitivity analyses were performed by changing and/or removing parameters	<p>Efficiency Frontier (ICER) Strategy 1: -</p> <p><u>Dominated strategies*</u> Strategy 2, Strategy 3, Strategy 6, Strategy 7, Strategy 10, Strategy 13, Strategy 14, Strategy 15, Strategy 16, Strategy 17, Strategy 20, Strategy 21, Strategy 22, Strategy 24, Strategy 25, Strategy 26, Strategy 27, Strategy 28, Strategy 29</p> <p><u>Extendedly Dominated strategies</u> Strategy 2, Strategy 3, Strategy 4, Strategy 5, Strategy 11, Strategy 18, Strategy 19, Strategy 30</p> <p><u>Other strategies</u> Strategy 8: 5 990 805 € Strategy 9: 62 365 € Strategy 12: 10 258 € Strategy 23: 35 207 €</p> <p>Total costs of testing Strategy 1: 128 090 €, Strategy 2: 160 488 €, Strategy 3: 225 855 €,</p>	Sensitivity analyses exploring the impact of no testing: It is seen that, at low willingness-to-pay values (\leq £30 000 per QALY or 34 182 €, converted), no testing appears to be one of the options with the highest NMB values, owing to the high costs associated with testing. As the willingness-to-pay threshold increases to £50 000 per QALY or 56 971 €, converted, these strategies compare unfavourably with other strategies. This indicates that the cost of SARS-CoV-2 tests is, as expected, a key driver of the cost-effectiveness of SARS-CoV-2 testing.

							Strategy 4: 213 312 €, Strategy 5: 168 547 €, Strategy 6: 204 601 €, Strategy 7: 237 225 €, Strategy 8: 322 725 €, Strategy 9: 289 776 €, Strategy 10: 266 100 €, Strategy 11: 166 067 €, Strategy 12: 175 792 €, Strategy 13: 223 036 €, Strategy 14: 223 900 €, Strategy 15: 220 880 €, Strategy 16: 211 808 €, Strategy 17: 211 726 €, Strategy 18: 175 671 €, Strategy 19: 187 759 €, Strategy 20: 208 742 €, Strategy 21: 215 763 €, Strategy 22: 243 017 €, Strategy 23: 252 474 €, Strategy 24: 319 984 €, Strategy 25: 319 984 €, Strategy 26: 317 823 €, Strategy 27: 288 295 €, Strategy 28: 288 236 €, Strategy 29: 272 911 €, Strategy 30: 284 874 €	
Shlomain et al, 2020	Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA)	Direct and indirect costs	Appr. 6.5 months	The discount rate was 0 ¹	Modified Susceptible, Exposed, Infectious, Recovered, and Deceased (SEIRD) model	1) One-way sensitivity analysis (via Tornado diagram), 2) Probabilistic sensitivity analysis (via Monte Carlo simulation)	<p>ICER Isolation²: -</p> <p>National lockdown of the susceptible population³: 36 568 451 € cost per death averted, 3.6 million € cost per QALY</p> <p>Total costs Isolation²: 99 6 million €</p> <p>National lockdown of the susceptible population³: 10 13 million €</p>	Even after sensitivity analyses results, the outcomes remain similar - the difference in the number of deaths and ICER remain similar. Sensitivity analysis indicates that the transmission rate (b) is the parameter with the most influence on ICER.

Keogh-Brown et al, 2020	Macroeconomic analysis, including Cost of illness	Direct medical costs and indirect costs	Not clearly mentioned	Not applied	Computable General Equilibrium (CGE) model	Sensitivity analyses conducted. For each sensitivity analysis, the parameter concerned is decreased or increased by 50% to give an upper or lower limit value.	<p>Total health-related costs</p> <p>a) No action is taken to mitigate the virus spread</p> <p>Total health-related costs: 45 1 billion € Total hospital Costs: 798 million € Hospitalised fatalities: 342 million € Hospitalised recovered ICU: 342 million € Hospitalised recovered non-ICU: 114 million € Total labour supply losses: 44 3 billion € Hospitalised fatalities: 3 2 billion € Hospitalised recovered: 5 3 billion € Non-hospitalised recovered: 35 1 billion €</p> <p>b) Mitigation policy</p> <p>Total health-related costs: 60 5 billion € Hospital Costs, total: 798 million € Hospitalised intensive-care: 342 million € Hospitalised non-intensive-care: 342 million € Labour supply losses, total: 59 7 billion € Hospitalised fatalities: 2 28 billion € Hospitalised recovered: 5 6 billion € Non-hospitalised recovered: 51 04 billion €</p> <p>c) Suppression policy</p> <p>Total health-related costs: 58 6 billion € Hospital Costs, total: 798 million € Hospitalised intensive-care: 798 million € Hospitalised non-intensive-care: 342 million € Labour supply losses, total: 57 8 billion € Hospitalised fatalities: 114 million € Hospitalised recovered: 5 9 billion € Non-hospitalised recovered: 51 04 billion €</p>	<p>No action scenario</p> <p>The results indicate that respectively lowering and increasing the clinical attack rate, from central 48% value, changes the direct health-related economic burden to respectively 22 0 billion € and 69 6 billion € ($\pm 51-54\%$), and this is the epidemiological parameter to which the economic impacts are most sensitive. Lowering and increasing the overall and age-specific case fatality rates changes the economic burden to 43 6 billion € and 46 5 billion € ($\pm 3\%$),</p> <p>Variations in age-specific hospitalization rates</p> <p>This contributed to have a relatively small impact changing the economic burden to 41 6 billion € and 49 1 billion € ($\pm 7-8\%$).</p> <p>Varying age-specific ICU admission rates</p> <p>Has a small effect on economic burden estimates, changing the economic burden estimates to 44 3 billion € and 46 9 billion € ($\pm 4\%$).</p>
Águas et al, 2021	Cost-effectiveness	Direct medical	6 months	Not applied	Decision state	Sensitivity analyses through Latin-hypercube	<p>ICER</p> <p>No dexamethasone treatment: -</p>	Sensitivity of ICER estimates to assumptions regarding the

	ss analysis (CEA)	costs			transition model	sampling and 1 million iterations	Dexamethasone treatment: 1 071 € (90% CI: 74 06 € to 2 301 6 €) Incremental cost No dexamethasone treatment: - Dexamethasone treatment: 97 million € (90% CI: 6 8 million € to 376 million €)	probability of receiving oxygen therapy when needed and the efficacy of dexamethasone when not receiving oxygen: The results show non-significant differences in the median ICERs for the explored parameter ranges.
Miles et al, 2020	Cost-benefit analysis (CBA)	Direct and indirect costs	4 months	Not applied	Yes, but the type has not been clearly specified	Not applied	Benefits, costs and net benefits, 1 Life saved = 5 QALYs – scenario of i) 9% GDP loss, ii) 15% GDP loss, iii) 20 % GDP loss, iv) 25% GDP loss <u>Lives not lost</u> Scenario a) 440 000 Benefits: i) 59 5 billion €, ii) 59 5 billion €, iii) 59 5 billion €, iv) 59 5 billion €, Costs: i) -158 8 billion €, ii) -262 1 billion €, iii) -349 4 billion €, iv) -639 2 billion €, Net benefits: i) -99 3 billion €, ii) -202 5 billion €, iii) -289 9 billion €, iv) -552 1 billion € Scenario b) 50 000 Benefits: 7 15 billion € Costs: -158 8 billion € Net benefits: -151 6 billion € e) 20 000 Benefits: 2 4 billion € Costs: -158 8 billion € Net benefits: -165 45 billion € Cost of easing - in case of each add. death = 5 QALY valued at £30,000 a) Continue lockdown (0 7): - b) Ease scenario I (0 9): 1 07 € c) Ease scenario II (1): 2 6 € d) Ease scenario III (1 15): 9 050 € Cost of easing - in case of each add. death	Not applied

							<p>= 5 QALY valued at £30,000</p> <p>a) Continue lockdown (0 7): -</p> <p>b) Ease scenario I (0 9): 2 01 €</p> <p>c) Ease scenario II (1): 4 9 €</p> <p>d) Ease scenario III (1 15): 17 02 €</p>	
Shaker et al, 2021	Cost-effectiveness analysis (CEA)	1. Direct medical costs for healthcare perspective , 2. Direct and indirect costs for societal perspective	1 year	Not applied	Decision tree	Deterministic and probabilistic sensitivity analyses	<p>ICER (cost per death averted) - Societal perspective</p> <p>Universal Covid-19 vaccination: 52 033 €</p> <p>Risk-stratified vaccination: -</p> <p>ICER (cost per death averted) – Healthcare perspective</p> <p>Universal Covid-19 vaccination</p> <p>a) Base-case: -</p> <p>b) Higher COVID risk; Lower anaphylaxis risk: -</p> <p>c) Lower COVID risk; Higher anaphylaxis risk: 1 213 486 €</p> <p>d) Second-order Monte-Carlo simulations (n = 10,000 simulations): -</p> <p>Risk-stratified vaccination</p> <p>a) Base-case: - 52 575 €</p> <p>b) Higher COVID risk; Lower anaphylaxis risk: - 238 169 €</p> <p>c) Lower COVID risk; Higher anaphylaxis risk: -</p> <p>d) Second-order Monte-Carlo simulations (n = 10,000 simulations): -141 462 €</p> <p>Cost-savings – Societal perspective</p> <p>Universal Covid-19 vaccination: 395 816 347 € compared to risk-stratified vaccination</p> <p>Cost-savings – Healthcare perspective</p> <p>Universal Covid-19 vaccination, compared to risk-stratified vaccination</p> <p>a) Base-case: 399 941 958 €</p> <p>b) Higher COVID risk; Lower anaphylaxis</p>	<p>a) In one-way sensitivity analysis when the risk of vaccine anaphylaxis exceeds 0.8%, risk stratification was the most cost-effective strategy (WTP = 10 000 000 per death prevented).</p> <p>b) Two-way sensitivity analysis of anaphylaxis risk and COVID-19 risk</p> <p>As risk of COVID-19 increased, cost-effectiveness of a risk-stratified approach required vaccine deferral at higher anaphylaxis risk thresholds. Moreover, in tornado diagram results, as vaccine anaphylaxis risk exceeded 0.8%, a risk-stratification approach was cost-effective (WTP = 10 000 000 per death prevented).</p> <p>c) Probabilistic sensitivity analysis</p> <p>Demonstrated universal vaccination strategy to be the most cost-effective strategy in 99.58% of simulations.</p>

							<p>risk: 122 109 684 659 €</p> <p>c) Lower COVID risk; Higher anaphylaxis risk: 50 975 388 861 €</p> <p>d) Second-order Monte-Carlo simulations (n = 10,000 simulations): 13 580 336 600 €</p>	
Miles et al, 2021	Cost-effectiveness analysis (CEA)	Indirect costs	6 months	Not applied	Simulation model	<p>Sensitivity analysis, by making 7 assumptions: 1) Seasonality Colder March = Winter Reproduction Rates, 2) Virus Base Reproduction Rate Increases: +10%, 3) The virus remains Infectious: 14 d, 4) Vaccine Effectiveness falls to Round 1:50% + Round 2:15%, 5) Vaccination Delivery Rate falls to 2 000 000/wk, 6) Worst Case (1,2,4,5 together), 7) Opportunity Vaccine Effectiveness Round 1 = 80%, Round 2 = 10% & Delivery 3 000 000/wk</p>	<p>Cost per life-year saved</p> <p>a) Base—no transition (0 wk high then 0 wk medium then 26 wk low): -</p> <p>b) I—short transition (8 wk medium then 18 wk low): -206 888 €</p> <p>c) II—long transition (4 wk high then 12 wk stepped reduction—medium): -507 922 €</p> <p>d) III—keep at high for 26 wk: -1 553 988 €</p>	<p>GDP/life-year saved vs base £k (€), in different physical restriction scenarios</p> <p>1) Base: 0wHI□0wMED□26wLO, 2) I: 0wHI□8wMED□18wLO, 3) II: 4wHI□12wMED□9wLO, 4) III: 26wHI□0wMED□0wLO</p> <p>Seasonality Colder March = Winter Reproduction Rates:</p> <p>1) -, 2) -147 611 €, 3) -360 311 €, 4) -1 093 720 €</p> <p>Virus Base Reproduction Rate Increases: +10%:</p> <p>1) -, 2) -67 413 €, 3) -167 370 €, 4) -509 085 €</p> <p>The virus remains Infectious: 14 days:</p> <p>1) -, 2) -154 585 €, 3) -361 473 €, 4) -1 087 908 €</p> <p>Vaccine Effectiveness falls to Round 1:50% + Round 2:15%:</p> <p>1) -, 2) -76 711 €, 3) -195 266 €, 4) -593 933 €</p> <p>Vaccination Delivery Rate falls to 2 000 000/wk:</p> <p>1) -, 2) -145 287 €, 3) -363 798 €, 4) -1 106 505 €</p> <p>Worst Case (1,2,4,5 together):</p> <p>1) -, 2) -48 816 €, 3) -119 716 €, 4) -363 798 €</p> <p>Opportunity Vaccine Effectiveness</p>

								Round 1 = 80%, Round 2 = 10% & Delivery 3 000 000/wk: 1) -, 2) -364 613 €, 3) -1 463 329 €, 4) -4 441 130 €
Zala et al, 2020	Cost-utility analysis (CUA)	Direct and indirect costs	Not clearly specified (hypothetical suppression policies until late 2021)	Not applied	Imperial model–projected suppression policy	Sensitivity analysis has been performed in parameters: a) No death-related healthcare cost-saving, b) Unemployment QALY loss included, c) End-of-life cost included, d) Net national income loss 50% less, e) Net national income loss 50% more	<p>ICER (cost per QALY) <u>Base-case results</u></p> <p>Suppression policy 1₄:: 22 842 € Suppression policy 1₅:: 38 757 € Suppression policy 2₆: 24 381 € Suppression policy 2₇: 44 532 €</p> <p>Incremental costs <u>Base-case results</u></p> <p>Suppression policy 1₄: 99 674 508 225 € Suppression policy 1₅: 81 997 186 965 € Suppression policy 2₆: 99 732 793 629 € Suppression policy 2₇: 82 055 472 369 €</p>	<p>ICER (cost per QALY) Scenarios followed by:</p> <p>1) No death-related healthcare cost saving, 2) Unemployment QALY loss included, 3) End-of-life cost included, 4) Net national income loss 50% less, 5) Net national income loss 50% more</p> <p>Suppression policy 1₄: 1) 19 475 €, 2) 30 389 €, 3) 22 812 €, 4) 98 911 €, 5) 32 426 € Suppression policy 1₅: 1) 35 389 €, 2) 75 518 €, 3) 38 726 €, 4) 17 817€, 5) 56 329 € Suppression policy 2₆: 1) 21 014 €, 2) 32 247 €, 3) 24 351 €, 4) 10 565 €, 5) 34 831 € Suppression policy 2₇: 1) 41 165 €, 2) 91 319 €, 3) 44 501 €, 4) 20 490 €, 5) 65 207 €</p> <p>Incremental costs</p> <p>Suppression policy 1₄: 1) 84 978 298 977 €, 2) 99 674 508 225 €, 3) 99 540 957 789 €, 4) 43 157 324 544 €, 5) 141 495 452 558 € Suppression policy 1₅: 1) 99 674 507 439 €, 2) 99 674 507 439 €, 3) 99 540 958 299 €, 4) 43 157 323 758 €, 5) 141 495 452 008 € Suppression policy 2₆: 1) 85 956 924 826 €, 2) 99 732 793 629 €, 3) 99 607 606 958 €, 4) 43 215 609 948 €, 5) 141 495 452 008 €</p>

							Suppression policy 2: 1) 75 850 393 534 €, 2) 82 055 472 369 €, 3) 81 999 084 407 €, 4) 37 754 592 049 €, 5) 120 151 273 854 €
Sheinson et al, 2021	Cost-effectiveness analysis (CEA)	Direct and indirect costs	Lifetime	3% for both costs and health outcomes	Short-term acute care decision tree followed by a post-discharge three-state Markov cohort model	Scenario analyses, univariate & probabilistic sensitivity analyses	<p>ICER (cost per QALY) 1) Payer perspective, 2) Societal perspective</p> <p>Treatment in the hospital with Covid-19 treatments a) With Bundled payment: 1) 18 593 € compared to best supportive care, 2) 9 317 € compared to best supportive care b) With FFS payment: 1) 15 784 € compared to best supportive care, 2) 6 508 € compared to best supportive care</p> <p>Total costs 1) Payer perspective, 2) Societal perspective Treatment in the hospital with Covid-19 treatments a) With Bundled payment: 1) 233 501 €, 2) 248 321 € b) With FFS payment: 1) 235 278 €, 2) 250 097 €</p> <p>Best supportive care a) With Bundled payment: 1) 225 372 €, 2) 244 247 € b) With FFS payment: 1) 228 376 €, 2) 247 252 €</p>

Univariate SA results
All univariate sensitivity analyses produced upper bound cost per QALY estimates well below commonly accepted WTP thresholds.

Probabilistic SA results (5000 draws)
For the base case clinical profile, upper bounds of 95% credible intervals ranged from 14 800 € (FFS, including societal impacts) to 24 569 € (health payer, without societal impacts). Over 99% of draws had a cost per QALY gained below the \$100,000 and \$150,000 WTP thresholds across all clinical profiles and all perspectives. Without including societal impacts, all draws resulted in the treatment of interest being more costly and more effective, with the exception of the base case treatment profile (which includes the LOS benefit), in which 1.4% of draws were cost-saving under the FFS perspective. When including societal impacts, draws for all three treatment profiles were similarly clustered in the northeast and southeast quadrants, with 18.4% and 15.6% of draws resulting in cost-saving scenarios for health payer and FFS perspectives, respectively

Neilan et al, 2020	Cost-utility analysis (CUA)	Direct medical and non-medical costs	6 months	3% year for health benefits (no discount for costs at base-case analysis)	Microsimulation model (Clinical and Economic Analysis of COVID-19 Interventions model)	Scenario analyses, 1-way and multiway sensitivity analyses	<p>ICER (Cost/QALY), per reproduction number scenarios: 1) Slowing (Re = 0.9), 2) Intermediate (Re = 1.3), 3) Surging Re = 2.0)</p> <p>Hospitalized: 1) Dominated, 2) Dominated, 3) 26 208 €</p> <p>Symptomatic: 1) N/A, 2) N/A, 3) N/A</p> <p>Symptomatic + Asymptomatic once: 1) 154 069 €, 2) 87 359 €, 3) Dominated</p> <p>Symptomatic + Asymptomatic monthly: 1) 721 107 €, 2) 227 927 €, 3) 26 207 €</p> <p>Total costs, per reproduction number scenario</p> <p>i) Slowing (Re = 0.9), ii) Intermediate (Re = 1.3), iii) Surging Re = 2.0</p> <p>Hospitalized: i) 349 034 504 €, ii) 674 952 259 €, iii) 2 189 550 522 €</p> <p>Symptomatic: i) 272 231 745 €, iii) 388 267 382 €, iii) 1 277 129 797 €</p> <p>Symptomatic + Asymptomatic once: i) 480 874 953 €, ii) 577 593 158 €, iii) 1 454 284 097 €</p> <p>Symptomatic + Asymptomatic monthly: i) 1 607 487 765 €, ii) 1 660 679 799 €, iii) 2 189 550 522 €</p>	<p>In 1-way sensitivity analyses, the economically preferred strategy in each epidemic scenario was most sensitive to test acceptance, the transmission reduction after a positive PCR test, and PCR test costs. In the surging scenario, symptomatic + asymptomatic monthly would not be cost-effective in assumption of low-test acceptance (15%), half the transmission reduction after a positive test (33%), or triple PCR test costs (122 €). Symptomatic + asymptomatic monthly would become cost-effective in the intermediate and slowing scenarios only with reductions in test costs (intermediate: ≤ 10.5 €; slowing: ≤ 4 €). If costs decrease for PCR assays, many combinations of program and assay costs symptomatic + asymptomatic monthly strategy would be cost-effective or cost-saving.</p> <p>Holding other parameters equal to the base case, symptomatic + asymptomatic monthly would become cost-effective at an $Re \geq 1.6$. In the surging scenario, symptomatic + asymptomatic monthly would no longer be cost-effective if tests occur more frequently than every 30 days; however, if test costs were ≤ 4 €, then testing as frequently as every 14 days would be cost-effective in all epidemic scenarios. While total costs would vary widely with rates</p>
--------------------	-----------------------------	--------------------------------------	----------	---	--	--	--	--

							of COVID-19–like illness, cost-effectiveness conclusions would not change. Conclusions are similar even when costs associated with lost productivity or averted COVID-19–related mortality are included	
Baggett et al, 2020	Cost-effectiveness analysis (CEA) and Budget-Impact analysis (BIA)	Direct medical and non-medical costs	4 months	Not applied	Microsimulation model (Clinical and Economic Analysis of COVID-19 interventions model)	One-way and two-way sensitivity analyses	<p>Total costs, per reproduction number scenario i) Slowing (Re, 0.9), ii) Growing (Re, 1.3), iii) Surging (Re, 2.6)</p> <p>No intervention: i) 428 853 €, ii) 1 160 285 €, iii) 4 842 859 € Symptom screening, PCR, and hospital: i) 883 913 €, ii) 1 273 851 €, iii) 10 022 447 € Symptom screening, PCR, and ACS: i) 209 661 €, ii) 324 816 €, iii) 2 594 559 € Universal PCR testing and hospital: i) 1 579 000 €, ii) 2 089 465 €, iii) 10 255 933 € Universal PCR and ACS: i) 973 655 €, ii) 1 132 488 €, iii) 3 290 253 € Universal PCR and temporary housing: i) 30 936 165 €, ii) 30 952 049 €, iii) 31 067 203 € Hybrid hospital: i) 1 591 520 €, ii) 1 880 598 €, iii) 9 690 483 € Hybrid ACS: i) 984 772 €, ii) 1 052 277 €, iii) 2 881 255 €</p> <p>ICER (Cost per case prevented), per reproduction number scenario i) Slowing (Re, 0.9), ii) Growing (Re, 1.3), iii) Surging (Re, 2.6)</p>	<p>1-way sensitivity analyses results If PCR cost decreased from 40 25 €, to 19 85 €, with an Re of 2.6, the hybrid ACS strategy became cost-saving compared with the symptom screening, PCR, and ACS strategy. With an Re of 2.6, the hybrid ACS strategy with universal PCR testing every 7 rather than every 14 days was associated with 29% fewer infections (incremental cost of 794.17 €/case prevented compared with testing every 14 days). Testing every 3 days had fewer infections, at 1 588 €/case prevented.</p> <p>In other Re scenarios, the hybrid ACS strategy did not result in a cost per case prevented below 15 883 €, compared with the symptom screening, PCR, and ACS strategy, regardless of universal testing frequency.</p> <p>Although the universal PCR with temporary housing strategy had the lowest number of cases in all scenarios, with an Re of 2.6, daily costs of temporary housing needed to be 15 9 €, per day or less to have an incremental cost per case prevented of 794 19 €, or less</p>

							<p>No intervention: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Symptom screening, PCR, and hospital: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Symptom screening, PCR, and ACS: i) N/A, ii) N/A, iii) N/A</p> <p>Universal PCR testing and hospital: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Universal PCR and ACS: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Universal PCR and temporary housing: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Hybrid hospital: i) Dominated, ii) 303 374 €, iii) Dominated</p> <p>Hybrid ACS: i) 53 386 €, ii) 21 443 €, iii) 794 17 €</p>	<p>compared with the hybrid ACS strategy. In the lower Re scenarios, the universal PCR and temporary housing strategy had higher costs per case prevented.</p> <p>2-way sensitivity analyses results</p> <p>In several combinations, hybrid ACS strategy was cost-saving or had an incremental cost per case prevented of 714 19 € to 2 383 € compared with the symptom screening, PCR, and ACS strategy.</p>
Currie et al, 2020	Cost-minimization analysis (CMA)	Direct medical and non-medical costs	1 month	Not applied	Community model pathway for COVID-19 testing	Not applied	<p>Average cost per test</p> <p>Home (community) testing: 52 08 €</p> <p>Hospital standard testing (one ambulance dispatched): 115 20 €</p> <p>Hospital standard testing (two ambulances dispatched): 230 38 €</p> <p>Total cost, for 173 tests</p> <p>Home (community) testing (with courier costs): 9 010 €</p> <p>Hospital standard testing (one ambulance dispatched): 19 928 €</p> <p>Hospital standard testing (two ambulances dispatched): 39 856 €</p> <p>Overall cost-savings</p> <p>Community testing: 28 522 € compared to hospital standard testing</p>	Not applied
Sandmann	Cost-	Direct	10 years	For base-	Age-	Deterministic and	Net monetary value	In sensitivity analyses with a longer

et al, 2021	effectiveness analysis (CEA)	medical costs		case: 3,5% for costs and benefits For sensitivity analysis: Variation between 0% - 10%	structured dynamic transmission and economic model (CovidM)	probabilistic sensitivity analyses	<p>a) healthcare perspective, b) societal perspective (in case of 15% daily GDP Loss)</p> <p>1) Initial Lockdown only No vaccination: a) -554 billion € (95% UI -419 billion € to -729 billion €), b) -8 00 trillion € (95% UI -3 4 trillion € to -17 1 trillion €) Vaccination, worst case: a) -490 billion € (95% UI -365 billion € to -627 billion €), b) -6 8 trillion € (95% UI -2 3 trillion € to -15 9 trillion €) Vaccination, best case: a) -160 billion € (95% UI -137 billion € to -216 billion €), b) -2 3 trillion € (95% UI -1 1 trillion € to -5 7 trillion €)</p> <p>2) No lockdown, Incidence trigger of increased physical distancing No vaccination: a) -513 billion € (95% UI -399 billion € to -684 billion €), b) -5 7 trillion € (95% UI -2 3 trillion € to -12 5 trillion €) Vaccination, worst case: a) -467 billion € (95% UI -353 billion € to -581 billion €), b) -5 7 trillion € (95% UI -2 28 trillion € to -12 5 trillion €) Vaccination, best case: a) -148 billion € (95% UI -120 billion € to -199 billion €), b) not specific values (related to zero net monetary value)</p> <p>3) No lockdown, Incidence trigger of increased physical distancing (10 cases/100 000) No vaccination: a) -80 billion € (95% UI -57 billion € to -103 billion €), b) -45 6 trillion € (95% UI -20 5 trillion € to -106 trillion €) Vaccination, worst case: a) -68 billion €</p>	<p>duration of natural immunity, the incremental economic value of immunisation decreases, potentially becoming lower than no vaccination for long durations of natural immunity and 50% vaccine efficacy against disease (worse-case scenario). Similarly, with a longer duration of vaccine-induced protection against disease or infection, the economic value of vaccination compared with no vaccination increases.</p>
-------------	------------------------------	---------------	--	---	---	------------------------------------	---	---

								<p>(95% UI -57 billion € to -91 billion €), b) -41 trillion € (95% UI -19 4 trillion € to -96 8 trillion €)</p> <p>Vaccination, best case: a) -57 billion € (95% UI -46 billion € to -68 billion €), b) 9 1 trillion € (95% UI -3 4 trillion € to -21 6 trillion €)</p> <p>4) No lockdown, Incidence trigger of increased physical distancing (20 cases/100 000)</p> <p>No vaccination: a) -103 billion € (95% UI -91 billion € to -137 billion €), b) -44 4 trillion € (95% UI -20 5 trillion € to -100 2 trillion €)</p> <p>Vaccination, worst case: a) -114 billion € (95% UI -80 billion € to -125 billion €), b) -37 6 trillion € (95% UI -19 3 trillion € to -93 4 trillion €)</p> <p>Vaccination, best case: a) -68 billion € (95% UI -57 billion € to -80 billion €), b) 8 0 trillion € (95% UI -2 3 trillion € to -20 5 trillion €)</p> <p>5) No lockdown, Incidence trigger of increased physical distancing (30 cases/100 000)</p> <p>No vaccination: a) -125 billion € (95% UI -108 billion € to -160 billion €), b) -43 3 trillion € (95% UI -19 3 trillion € to -96 8 trillion €)</p> <p>Vaccination, worst case: a) -125 billion € (95% UI -90 billion € to -125 billion €), b) -36 5 trillion € (95% UI -17 1 trillion € to -88 9 trillion €)</p> <p>Vaccination, best case: a) -80 billion € (95% UI -57 billion € to -80 billion €), b) -6 8 trillion € (95% UI -1 7 trillion € to -15 9 trillion €)</p>
--	--	--	--	--	--	--	--	--

						<p>6) No lockdown, Incidence trigger of increased physical distancing (40 cases/100 000) No vaccination: a) -148 billion € (95% UI -114 billion € to -182 billion €), b) -38 7 trillion € (95% UI -20 5 trillion € to -92 3 trillion €) Vaccination, worst case: a) -148 billion € (95% UI -114 billion € to -160 billion €), b) -47 9 trillion € (95% UI -15 9 trillion € to -85 5 trillion €) Vaccination, best case: a) -80 billion € (95% UI -74 billion € to -108 billion €), b) -5 7 trillion € (95% UI -1 7 trillion € to -13 7 trillion €)</p> <p>7) No lockdown, Incidence trigger of increased physical distancing (50 cases/100 000) No vaccination: a) -171 billion € (95% UI -137 billion € to -216 billion €), b) -37 6 trillion € (95% UI -18 2 trillion € to -87 7 trillion €) Vaccination, worst case: a) -160 billion € (95% UI -137 billion € to -205 billion €), b) -45 6 trillion € (95% UI -14 8 trillion € to -79 8 trillion €) Vaccination, best case: a) -91 billion € (95% UI -97 billion € to -114 billion €), b) -5 2 trillion € (95% UI -1 5 trillion € to -13 1 trillion €)</p> <p>8) No lockdown, Incidence trigger of increased physical distancing (60 cases/100 000) No vaccination: a) -194 billion € (95% UI</p>	
--	--	--	--	--	--	---	--

							<p>-148 billion € to -228 billion €), b) -35 8 trillion € (95% UI -16 6 trillion € to -84 3 trillion €)</p> <p>Vaccination, worst case: a) -205 billion € (95% UI -148 billion € to -228 billion €), b) -42 7 trillion € (95% UI -12 5 trillion € to -75 7 trillion €) Vaccination, best case: a) -97 billion € (95% UI -103 billion € to -120 billion €), b) -4 8 trillion € (95% UI -1 3 trillion € to -12 7 trillion €)</p> <p>9) No lockdown, Incidence trigger of increased physical distancing (100 cases/100 000)</p> <p>No vaccination: a) -239 billion € (95% UI -194 billion € to -308 billion €), b) -33 6 trillion € (95% UI -16 6 trillion € to -77 4 trillion €)</p> <p>Vaccination, worst case: a) -228 billion € (95% UI -182 billion € to -285 billion €), b) -30 8 trillion € (95% UI -11 1 trillion € to -66 1 trillion €)</p> <p>Vaccination, best case: a) -103 billion € (95% UI -108 billion € to -125 billion €), b) -4 3 trillion € (95% UI -1 2 trillion € to -12 1 trillion €)</p>	
Barnett-Howell et al, 2021	Benefit-cost analysis	Not clearly specified	Not clearly specified	Not applied	Age-structured compartmental Susceptible-Exposed-Infected-Recovered (SEIR) model	Not applied	<p>Value of the total statistical life (VSL) lost</p> <p>Unmitigated spread of Covid-19: a) US: 38 9 billion €, b) UK: 7 1 billion €, c) Mexico: 1 58 billion €</p> <p>Individual distancing policy: a) US: 38 9 billion €, b) UK: 36 5 billion €, c) Mexico: 1 43 billion €</p> <p>Broad physical distancing policy: a) US: 30 2 billion €, b) UK: 6 03 billion €, c) Mexico: 1 03 billion €</p> <p>Physical distancing +: a) US: 25 4 billion €, b) UK: 5 2 billion €, c) Mexico: 794</p>	Not applied

							million € Full lockdown policies: a) US: 23 billion €, b) UK: 4 76 billion €, c) Mexico: 794 million €	
Gandjour et al, 2020	Cost-effectiveness analysis (adopted outcomes)	Indirect costs	1 year	Not applied	Decision Life-table model	One-way sensitivity analyses	<p>Value of LYs gained, per capita</p> <p>i) Independence assumption scenario No intervention: 0 Shutdown in scenario of “flattening the curve”: 3 472 € Shutdown in scenario of “Squashing the curve”: 38 166 € ICU capacity exceeded by 50%: 2 165 € ICU capacity exceeded by 100%: 1 020 € ICU capacity exceeded by 200%: 327 € ICU capacity exceeded by 300%: 80 5 €</p> <p>i) Harvesting assumption scenario No intervention: 0 Shutdown in scenario of “flattening the curve”: 4 093 € Shutdown in scenario of “Squashing the curve”: 38 115 € ICU capacity exceeded by 50%: 2 518 € ICU capacity exceeded by 100%: 1 173 € ICU capacity exceeded by 200%: 379 € ICU capacity exceeded by 300%: 93 €</p>	Using lower and higher estimates based on the sensitivity analysis, the economic value ranges between 1% and 12% of the GDP.
Gandjour et al, 2021	Cost-effectiveness analysis (CEA) and Return on Investment (ROI) analysis	Direct medical and non-medical costs	Lifetime	Base-case analysis: No discounting Sensitivity analysis: 3% discount rate for the costs and 2% for health benefits	Decision model	One-way deterministic analyses and threshold sensitivity analysis	<p>Marginal cost per life year gained</p> <p>i) Independence assumption scenario By adding 1 ICU: 22 986 € By adding 10000 ICU: 29 627 €</p> <p>ii) Harvesting assumption scenario By adding 1 ICU: 14 306 € By adding 10000 ICU: 18 389 €</p>	One-way sensitivity analysis results The variables with the greatest impact on net monetary benefit were the mortality rates in the ICU and after discharge threshold sensitivity analysis results: Expanding staffed ICU bed capacity by another 10 000 beds or 102% of the available capacity (9 765 beds on October 26, 2020) is projected to increase societal costs by 51 1 billion €.

Bartsch et al, 2021	Cost of illness analysis	Direct and indirect costs	2,5 years	3% for future costs	Computational model	<p>Scenarios using Monte Carlo simulations of 2,000 trials - Sensitivity analyses varied population coverage (25%–75%), vaccination cost (\$45–\$125), NPI use, and the probability of ambulatory care and deterministic analysis also included in the study</p>	<p>Direct and indirect medical costs, billion, no NPI use before vaccination onset VS NPI use similar to current US measures - per vaccine efficacy scenarios: 1) 20% VE, 2) 50% VE, 3) 80%</p> <p>Vaccine that prevents infection, 5% have already been infected</p> <p>NO NPI USE</p> <p>1) a) Median direct costs: 263 7 € (95% UI 230 € - 293 6 €), b) median indirect costs: 220 € (95% UI 95 6 € - 497 9 €)</p> <p>2) a) Median direct costs: 208 3 € (95% UI 169 9 € - 238 €), b) median indirect costs: 171 5 € (95% UI 169 9 € - 238 €)3) a) Median direct costs: 147 9 € (95% UI 109 7 € - 179 6 €), b) median indirect costs: 119 € (95% UI 51 2 € - 256 2 €)</p> <p>NPI USE</p> <p>1) a) Median direct costs: 223 3 € (95% UI 177 1 € - 262 2 €), b) median indirect costs: 182 3 € (95% UI 79 4 € - 397 5 €)</p> <p>2) a) Median direct costs: 172 € (95% UI 142 1 € - 204 9 €), b) median indirect costs: 138 3 € (95% UI 58 4 € - 303 7 €)3) a) Median direct costs: 119 4 € (95% UI 92 € - 141 7 €), b) median indirect costs: 94 7 € (95% UI 39 5 € - 203 4 €)</p> <p>Vaccine that reduces severe disease Direct & indirect costs</p> <p>NO NPI USE</p> <p>1) N/A, 2) N/A, 3) N/A</p> <p>NPI USE</p> <p>1) N/A, 2) N/A, 3) N/A</p> <p>Vaccine that prevents infection, 25% have already been infected</p> <p>NO NPI USE</p> <p>1) a) Median direct costs: 273 2 € (95% UI</p>	<p>Overall, the duration of the infectious period, followed by vaccine efficacy and vaccination coverages are the largest drivers of total cases and third-party paper costs when vaccinating. Hourly wage, then vaccine efficacy, followed by the duration of infectiousness are the largest drivers of total societal costs when vaccinating.</p> <p>With the scenario of a vaccine that prevents infection</p> <p>1) Duration of Infectiousness gives an estimation of impact on third-party total costs with a range of -15 883 € (minimum) to 49 238 € (maximum). Regarding the impact on total cases, the minimum impact is -22 million with the maximum at 43 million</p> <p>2) Vaccine Efficacy gives an estimation of impact on third-party total costs with a range of -30 178 € (minimum)</p>
---------------------	--------------------------	---------------------------	-----------	---------------------	---------------------	--	--	--

						<p>241 2 € - 305 €), b) median indirect costs: 229 3 € (95% UI 101 4 € - 501 7 €)</p> <p>2) a) Median direct costs: 234 5 € (95% UI 202 € - 264 €), b) median indirect costs: 229 3 € (95% UI 101 4 € - 501 7 €)</p> <p>3) a) Median direct costs: 196 € (95% UI 167 3 € - 223 €), b) median indirect costs: 195 6 € (95% UI 119 1 € - 412 8 €)</p> <p>NPI USE</p> <p>1) a) Median direct costs: 231 7 € (95% UI 180 8 € - 274 7€), b) median indirect costs: 201 2 € (95% UI 82 3 € - 396 4 €)</p> <p>2) a) Median direct costs: 191 € (95% UI 142 7 € - 229 1 €), b) median indirect costs: 156 8 € (95% UI 66 9 € - 354 2 €)</p> <p>3) a) Median direct costs: 153 4 € (95% UI 116 6 € - 189 €), b) median indirect costs: 122 7 € (95% UI 47 3 € - 275 5 €)</p> <p>Vaccine that prevents infection, 50% have already been infected</p> <p>NO NPI USE</p> <p>1) a) Median direct costs: 285 8 € (95% UI 253 1 € - 305 €), b) median indirect costs: 238 8 € (95% UI 106 3 € - 501 7 €)</p> <p>2) a) Median direct costs: 262 8 € (95% UI 232 4 € - 291 2 €), b) median indirect costs: 214 6 € (95% UI 93 5 € - 463 9 €)</p> <p>3) a) Median direct costs: 241 € (95% UI 214 7 € - 268 1 €), b) median indirect costs: 214 6 € (95% UI 93 5 € - 463 9 €)</p> <p>NPI USE</p> <p>1) a) Median direct costs: 263 7 € (95% UI 229 9 € - 293 6 €), b) 220 € (95% UI 95 6 € - 497 9 €)</p> <p>2) a) Median direct costs: 208 3 € (95% UI 169 9 € - 238 €), b) 171 5 € (95% UI 73 5 € - 389 8 €)3) a) Median direct costs: 147</p>
--	--	--	--	--	--	---

							9 € (95% UI 109 7 € - 179 6 €), b) median indirect costs: 119 € (95% UI 51 2 € - 256 2 €)	
Thom et al, 2021	Cost-effectiveness analysis (CEA)	Direct medical costs	7 months	Not applied	Age-structured deterministic mathematical model of SARS-CoV-2 transmission	A sensitivity analysis (the type is not specified) with a high standardized mortality ratio of 2.0 has been performed	<p>Incremental health-related net benefit, per capita at £20 000 (22 789 €)/QALY Scenario A⁸: a) UK: 1 146 1 €, b) Ireland: 1 133 3 €, c) Spain: 1 700 7 €, d) Germany: 1 801 7 €, e) Sweden: 1 581 8 € Scenario B⁹: a) UK: 251 2 €, b) Ireland: 516 5 €, c) Spain: 415 5 €, d) Germany: 245 3 €, e) Sweden: 564 5 € Scenario C¹⁰: a) UK: 1 865 7 €, b) Ireland: 1 374 8 €, c) Spain: 2 042 5 €, d) Germany: 2 173 6 €, e) Sweden: 1 900 7 € Scenario D¹¹: N/A</p> <p>Incremental costs, billion Scenario A⁸: UK: -37 53 €, b) Ireland: -190€, c) Spain: -27 16 €, d) Germany: -49 25 €, e) Sweden: -5 45 € Scenario B⁹: a) UK: -9 81 €, b) Ireland: -0 93 €, c) Spain: -9 12 €, d) Germany: -9 15 €, e) Sweden: -2 32 € Scenario C¹⁰: a) UK: -43 62 €, b) Ireland: -2 32 €, c) Spain: -32 76 €, d) Germany: -60 15 €, e) Sweden: -6 57 € Scenario D¹¹: N/A</p> <p>Incremental benefit, millions of QALYs Scenario A⁸ : UK: 3 166, b) Ireland: 0 162, c) Spain: 2 297, d) Germany: 4 467, e) Sweden: 0 463 Scenario B⁹: a) UK: 0 319, b) Ireland: 0</p>	No specific relevant data. The authors indicated that they could not conduct probabilistic sensitivity analysis and that the costs of hospitalization were assumed to be independent of the number of hospitalizations.

							071, c) Spain: 0 452, d) Germany: 0 501, e) Sweden: 0 149 Scenario C ¹⁰ : a) UK: 3 649, b) Ireland: 0 197, c) Spain: 2 754, d) Germany: 5 357, e) Sweden: 0 555 Scenario D ¹¹ : N/A	
Kohli et al, 2021	Cost-utility analysis (CUA)	Direct medical costs	1 year	3%	Markov model	Deterministic sensitivity analyses	<p>ICER (incremental cost per QALY gained), per age-based prioritization scenario</p> <p>Covid-19 vaccine 18–49 y: 74 652 € 50–64 y: 6 353 € 65+ y: Dominates</p> <p>ICER (incremental cost per QALY gained), per risk-based prioritization scheme</p> <p>Covid-19 vaccine No serious medical condition, 18–49 y: 270 018 € Serious medical condition, 18–64 y • No serious medical condition, 50–64 y: 7 942 € Nursing homes • 65 + y with or without serious medical condition: Dominates</p> <p>ICER (incremental cost per QALY gained), per occupational-based prioritization scheme</p> <p>Covid-19 vaccine 18–49 y: 74 652 € 50–64 y: 6 353 € 65+: Vaccination Dominates Priority and other critical occupations: 15 883 €</p>	<p>The incremental cost per QALY gained is most sensitive to changes in the attack rate, the vaccine price, and the costs of hospitalizations, but changes in the amount of disutility experienced by patients due to the morbidity associated with COVID-19 has minimal effect. Varying the expected age-specific baseline utility has more impact on this outcome.</p> <p>Under base case assumptions, a vaccine targeted at the entire population would have to be priced at over 119 € per dose (238 €per course) in order to exceed an incremental cost per QALY of over 39 709€. The incremental cost per QALY for the lowest risk individuals decreases as incidence of disease or vaccine efficacy decreases. For example, it is 19 854 € for those aged 18 to 49 years and 87 359 € for those aged 18 to 49 years with no comorbid conditions if the incidence pattern shifts and a higher number of deaths are seen in those under 50 years.</p>

							<p>Total costs (incl. vaccination and hospitalization costs) Covid-19 vaccine Per Vaccine supply scenario: 1) Low, 2) Medium, 3) High, 4) Immediate</p> <p>1) No priority: 22 615 €, Age-based: 22 013 €, Occupational/age-based: 22 214 €, Risk-group-based: 22 013 €</p> <p>2) No priority: 21 824 €, Age-based: 21 370 €, Occupational/age-based: 21 511 €, Risk-group-based: 21 370 €</p> <p>3) No priority: 20 752 €, Age-based: 20 509 €, Occupational/age-based: 20 532 €, Risk-group-based: 20 534 €,</p> <p>4) No priority: 20 330 €, Age-based: 20 330 €, Occupational/age-based: 20 330 €, Risk-group-based: 20 330 €</p> <p>No Covid-19 vaccine: 16 382 €</p>	
Chen et al, 2020	Cost of illness analysis	Direct medical costs	1 year	Not applied	Susceptible-Exposed-Infectious-Removed (SEIR) model	Sensitivity analysis was applied by varying the length of hospital stay to 7 days and dedicated beds availability to 80%, 90%, and 120%. However, the type of SA has not been specified.	<p>Total medical costs, i) in case of unlimited supply of hospital beds, ii) under different capacity scenarios a) constrained without sharing, b) constrained with sharing</p> <p>Stay-home for 0 days (unmitigated): i) 794 billion €, ii) a) 1 79 trillion €, b) 1 19 trillion €</p> <p>Stay-home for 30 days with VHI & SHI 60% compliance rate: i) 635 billion €, ii) a) 873 billion €, b) 611 billion €</p> <p>Stay-home for 30 days with VHI & SHI 70% compliance rate: i) 496 billion €, ii) a) 715 billion €, b) 516 billion €</p> <p>Stay-home for 30 days with VHI & SHI</p>	<p>Sensitivity analysis of the length of hospital stays, and dedicated bed capacity available to COVID-19 patients:</p> <p>In almost all cases, analysis shows 70% of dedicated bed capacity and an average 14 days hospital stay, can still lead to 100-200% increase in deaths, if the compliance is below 90% and no sharing of hospital beds is allowed. Even for the 7 days average hospital stay case, at least 70% or more compliance is needed to minimize the effect of shortage of beds on additional deaths.</p>

						<p>80% compliance rate: i) 222 billion €, ii) a) 278 billion €, b) 246 billion € Stay-home for 30 days with VHI & SHI 90% compliance rate: i) 79.4 billion €, ii) a) 79.4 billion €, b) 71.4 billion € Stay-home for 45 days with VHI & SHI 60% compliance rate: i) 596 billion €, ii) a) 834 billion €, b) 596 billion Stay-home for 45 days with VHI & SHI 70% compliance rate: i) 278 billion €, ii) a) 389 billion €, b) 298 billion € Stay-home for 45 days with VHI & SHI 80% compliance rate: i) 47.6 billion €, ii) a) 63.5 billion €, b) 47.6 billion € Stay-home for 45 days with VHI & SHI 90% compliance rate: i) 23.8 billion €, ii) a) 23.8 billion €, b) 19.8 billion € Stay-home for 60 days with VHI & SHI 60% compliance rate: i) 461 billion €, ii) a) 715 billion €, b) 536 billion € Stay-home for 60 days with VHI & SHI 70% compliance rate: i) 87.4 billion €, ii) a) 139 billion €, b) 95 billion € Stay-home for 60 days with VHI & SHI 80% compliance rate: i) 27.8 billion €, ii) a) 23.8 billion €, b) 19.8 billion € Stay-home for 60 days with VHI & SHI 90% compliance rate: i) 23.8 billion €, ii) a) 23.8 billion €, b) 16 billion €</p>	<p>Sensitivity analysis for the case when sharing of beds is allowed among hospitals in the neighboring HRR: Sharing helps eliminate almost all shortages in all mitigation scenarios. Even a 14 days hospital stay with just 70% of beds available can be enough to handle the demand if sharing among HRRs is allowed.</p> <p>Another sensitivity analysis of medical costs to different RO: Shows that when R0 is 2.6 and VHI compliance rate is 60%, the costs are much higher for a 30 days SH duration (pink circle) compared to 60 days SH duration (blue +). Although SH compliance is also slightly higher for this element in the last panel (80% vs. 90%), the costs are 15 times as much for SH duration of 30 days compared to 60 days; (2) sensitivity of costs to R0 decreases as the SH duration increases.</p>	
Losina et al, 2020	Cost-effectiveness and cost-utility analyses	Direct medical, non-medical and indirect costs	3,5 months	Not applied	Microsimulation model of SARS-CoV-2	Yes, by conducting sensitivity analysis (type not specified) and threshold analysis	<p>ICER, i) Cost/infection prevented, ii) Cost/QALY <u>a) Minimum physical distancing interventions, b) Extensive physical distancing interventions, c) Masks intervention, d) Combination of extensive physical distancing interventions and masks intervention</u></p>	<p>Results were most sensitive to test costs.</p> <p>In particular, the most influential factors affecting the value of RLT were test costs and frequency. If test costs were lowered to 0.79 € per test, then adding RLTq3 to Masks</p>

						<p>Residence-based isolation, incl. self-screen: a) i) 135 €, ii) 33 276 €, b) i) 95 €, ii) 20 728 €, c) i) 63 €, ii) 13 739 €, d) i) 79 €, ii) 20 251 €</p> <p>Designated space for isolation, incl. self-screen: a) i) strong dominance, ii) strong dominance, b) i) strong dominance, ii) strong dominance, c) i) 294 €, ii) 57 419 €, d) i) strong dominance, ii) strong dominance</p> <p>Designated spaces for isolation + 1-time laboratory testing: a) i) weak dominance, ii) weak dominance, b) i) strong dominance, ii) strong dominance, c) i) weak dominance, ii) strong dominance, d) i) strong dominance, ii) strong dominance</p> <p>Designated spaces for isolation + routine laboratory testing every 14 days: a) i) weak dominance, ii) weak dominance, b) i) 460 €, ii) weak dominance, c) i) 405 €, ii) 136 042 €, d) i) 1 596 €, ii) 644 391 €</p> <p>Designated spaces for isolation + routine laboratory testing every 7 days: a) i) 349 €, ii) 92 918 €, b) i) 468 €, ii) 171 065 €, c) i) 1 152 €, ii) 386 762 €, d) i) 1 152 €, ii) 386 762 €</p> <p>Designated spaces for isolation + routine laboratory testing every 3 days: a) i) 524 €, i) 150 734 €, b) i) 1 390 €, ii) 423 770 €, c) i) 2 033 €, ii) 550 996 €, d) i) 13 668 €, ii) 2 227 334 €</p>	<p>led to a favorable cost of 127 07 € per infection prevented (33 911 € per QALY) and adding RLTq14 to ExtSocDist+Masks led to 166 78 € per infection prevented (66 392 € per QALY).</p> <p>If the implementation cost of ExtSocDist doubled from 198 542 € to 397 085 €, ExtSocDist+ResIsol cost 198 5 € per infection prevented (42 091€ per QALY). Lowering the cost of designated isolation spaces from 23 8 € to 3 97 € per room per day reduced total costs attributable to COVID-19 mitigation by 07% to 1.7% (6 750 € to 11 357 €), depending on the strategy.</p>
--	--	--	--	--	--	---	---

Chen et al, 2020	Cost of illness analysis	Direct medical and indirect costs	1 year	Not applied	Susceptible -Exposed- Infectious-Removed (SEIR) model	Not applied	<p>Total costs No NPI applied: Approx. 993 billion €</p> <p>Stay-home for 30 days, with 60%-70%-80%-90% compliance rate: 1) 2 06 trillion €, 2) 2 14 trillion €, 3) 1 9 trillion €, 4) 1 8 trillion €</p> <p>Stay-home for 45 days, with 60%-70%-80%-90% compliance rate: 1) 2 6 trillion €, 2) 2 5 trillion €, 3) 2 46 trillion €, 4) 2 7 trillion €</p> <p>Stay-home for 60 days, with 60%-70%-80%-90% compliance rate: 1) 3 18 trillion €, 2) 3 01 trillion €, 3) 3 25 trillion €, 4) 3 49 trillion €</p>	Not applied
Vernaz et al, 2020	Cost analysis	Direct medical costs	Approx. 3 months	Not applied	Monte Carlo simulation model	Deterministic sensitivity analysis	<p>Total additional cost, attributable to LOS</p> <p>A single dose of 800 mg of hydroxychloroquine: Mean cost of 648 102 € for 93 patients (95% CI; 236 830 – 1 057 646)</p> <p>Lopinavir/ritonavir and hydroxychloroquine: Mean cost of 1 331 143 € for 158 patients (95% CI; 491 297 – 1 682 737)</p>	Sensitivity analysis results were similar to those reported as base-case results
Ebigbo et al, 2021	Cost-effectiveness analysis (CEA)	Direct medical, non-medical and indirect costs	Appr. 8,5 months	Not applied	Monte Carlo simulation model	Not applied	<p>ICER, per prevalence of asymptomatic infections: 1) 0.01□%, 2) 0.10□%, 3) 1□%, 4) 5□%</p> <p>Strategy 1₁₂: -</p> <p>Strategy 2₁₃: -</p> <p>Strategy 3₁₄ -: Laplace: 1) 265 485 €, 2) 12 029 €, 3) -13 317 €, 4) -15 570 €, Minimum: 1) 138 087 €, 2) -711 €, 3) -14 □282, 4) -15 824 €</p>	Not applied

						<p>Minimax: 1) 560 151 €, 2) 41 495 €, 3) -10 369 €, 4) -10 369 € C1 Width: 1) 265 421 €, 2) 26 542 €, 3) 26 542 €, 4) 531 €</p> <p>Strategy 4₁₅ : Laplace: 1) 428 183 €, 2) 17 828 €, 3) -23 207 €, 4) -26 854 € Minimum: 1) 221 921 €, 2) -2 798 €, 3) -25 270, 4) -27 269 € Minimax: 1) 905 260 €, 2) 65 536 €, 3) -18 436 €, 4) -25 900 € C1 Width: 1) 429 729 €, 2) 42 972 €, 3) 4 297 €, 4) 859 €</p> <p>Strategy 5₁₆: Laplace: 1) 1 632 368 €, 2) 148 718 €, 3) 352 €, 4) -12 836 € Minimum: 1) 886 619 €, 2) 74 142 €, 3) -7 105, 4) -14 327 € Minimax: 1) 3 357 256 €, 2) 321 206 €, 3) 17 602 €, 4) -9 386 € C1 Width: 1) 1 553 697 €, 2) 155 639 €, 3) 117 699 €, 4) 3 108 €</p> <p>Strategy 6₁₇: Laplace: 1) 1 736 817 €, 2) 158 913 €, 3) 673 €, 4) -13 356 € Minimum: 1) 943 487 €, 2) 79 172 €, 3) -7 206, 4) -14 942 € Minimax: 1) 3 351 759 €, 2) 341 999 €, 3) 19 024 €, 4) -9 686 € C1 Width: 1) 1 652 828 €, 2) 165 283 €, 3) 16 528 €, 4) 3 296 €</p> <p>Strategy 7₁₈ : Laplace: 1) 2 689 263 €, 2) 254 406 €, 3) 10 921 €, 4) -10 722 € Minimum: 1) 1 465 396 €, 2) 132 020 €, 3) -1 318, 4) -13 170 €</p>
--	--	--	--	--	--	---

						<p>Minimax: 1) 5 520 029 €, 2) 537 482 €, 3) 39 928 €, 4) -5 060 € C1 Width: 1) 2 549 812 €, 2) 254 982 €, 3) 25 497 €, 4) 5 100 €</p> <p>Strategy 8₁₉: Laplace: 1) 2 794 398 €, 2) 264 148 €, 3) 11 112 €, 4) -11 369 € Minimum: 1) 1 522 581 €, 2) 136 965 €, 3) -1 595, 4) -13 912 € Minimax: 1) 5 736 060 €, 2) 558 418 €, 3) 40 539 €, 4) -5 485 € C1 Width: 1) 2 649 709 €, 2) 264 970 €, 3) 26 497 €, 4) 5 299 €</p> <p>Total cost, per strategy Strategy 1₁₂ -: 161 436 € (dependent on both diagnostic yield of tests and prevalence)</p> <p>Strategy 2₁₃ : 161 436 €</p> <p>Strategy 3₁₄: 2 452 519 €</p> <p>Strategy 4₁₅ : 287 442 €</p> <p>Strategy 5₁₆: 1 722 968 € (dependent on both diagnostic yield of tests and prevalence)</p> <p>Strategy 6₁₇ : 1 824 450 €</p> <p>Strategy 7₁₈: 2 797 551 € (dependent on both diagnostic yield of tests and prevalence)</p> <p>Strategy 8₁₉: 2 902 205 €</p>		
Paltiel et al, 2020	Cost-effectiveness	Direct medical	2 months and 20	Not applied	Simple compartment	Yes, but the type is not specified - by varying the	ICER (cost/infection averted), per i) base case, ii) worst case, iii) best case	Varying the initial number of asymptomatic infections between 0

	ss- analysis (CEA) and Budget-Impact Assessment	and indirect costs	days		ntal epidemic model	initial number of asymptomatic infections between 0 and 100	<p>scenarios</p> <p>Symptom-based screening, with no test sensitivity: N/A</p> <p>Weekly screening, with 70% test sensitivity: i) 162 1 €, ii) Dominated, iii) 567 5 €</p> <p>Weekly screening, with 80% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Weekly screening, with 90% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Every 3 days screening, with 70% test sensitivity: i) 486 4 €, ii) Dominated, iii) 7 377 9 €</p> <p>Every 3 days screening, with 80% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Every 3 days screening, with 90% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Every 2 days screening, with 70% test sensitivity: i) 4 621 3 €, ii) 486 4 €, iii) 31 457 3 €</p> <p>Every 2 days screening, with 80% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Every 2 days screening, with 90% test sensitivity: i) Dominated, ii) Dominated, iii) Dominated</p> <p>Daily screening, with 70% test sensitivity: i) 23 025 €, ii) 3 567 €, iii) 103 858 €</p> <p>Daily screening, with 80% test sensitivity: i) 610 175 €, ii) 129 478 €, iii) 2 559 313 €</p> <p>Daily screening, with 90% test sensitivity: i) 1 372 528 €, ii) 306 060 €, iii) 5 540 542 €</p> <p>Total costs, per i) base case, ii) worst case, iii) best case scenarios</p>	and 100 did not materially change the findings
--	---	--------------------	------	--	---------------------	---	--	--

							<p>Symptom-based screening, with no test sensitivity: N/A</p> <p>Weekly screening, with 70% test sensitivity: i) 564 286 €, ii) 546 125 €, iii) 476 562 €</p> <p>Weekly screening, with 80% test sensitivity: i) 1 236 768 €, ii) 1 033 065 €, iii) 1 161 570 €</p> <p>Weekly screening, with 90% test sensitivity: i) 2 300 519 €, ii) 2 654 995 €, iii) 2 257 195 €</p> <p>Every 3 days screening, with 70% test sensitivity: i) 1 268 427 €, ii) 1 223 674 €, iii) 1 106 357 €</p> <p>Every 3 days screening, with 80% test sensitivity: i) 1 872 846 €, ii) 2 669 656 €, iii) 2 654 996 €</p> <p>Every 3 days screening, with 90% test sensitivity: i) 5 464 818 €, ii) 5 146 596 €, iii) 5 385 120 €</p> <p>Every 2 days screening, with 70% test sensitivity: i) 1 897 655 €, ii) 1 837 497 €, iii) 1 657 590 €</p> <p>Every 2 days screening, with 80% test sensitivity: i) 4 260 440 €, ii) 4 105 018 €, iii) 4 065 048 €</p> <p>Every 2 days screening, with 90% test sensitivity: i) 8 203 794 €, ii) 7 916 300 €, iii) 8 078 532 €</p> <p>Daily screening, with 70% test sensitivity: i) 2 928 191 €, ii) 3 608 637 €, iii) 3 240 935 €</p> <p>Daily screening, with 80% test sensitivity: i) 8 464 290 €, ii) 8 275 789 €, iii) 8 121 178 €</p> <p>Daily screening, with 90% test sensitivity: i) 16 301 784 €, ii) 19 666 200 €, iii) 16 143 119 €</p>	
Paltiel	Cost-	Direct and	2 months	Not applied	Simple	Sensitivity analyses -	ICER (Cost/infection averted), per i)	ICER (Cost/infection averted),

et al, 2021	effectiveness analysis (CEA)	indirect costs			compartmental epidemic model	<p>sensitivity to testing frequency (daily to once every 15 days), Sensitivity to Rt, Sensitivity to the Costs of Testing, Sensitivity to Behavioral Factors</p>	<p>worst-case, ii) base-case, iii) best-case behavioral scenarios Home-based SARS-COV-2 antigen testing: i) 17 472 €, ii) 6 266 €, iii) 5 075 €</p> <p>ICER (Cost/death averted), per i) worst-case, ii) base-case, iii) best-case behavioral scenarios Home-based SARS-COV-2 antigen testing: i) 3 287 871 €, ii) 1 135 666 €, iii) 849 764 €</p> <p>Total costs, per i) worst-case, ii) base-case, iii) best-case behavioral scenarios Home-based SARS-COV-2 antigen testing: i) 19 1 billion €, ii) 25 7 billion €, iii) 43 5 billion € No Home-based SARS-COV-2 antigen testing: 8 02 billion €, attributable to 2 17 billion € for inpatient severe disease, 3 0 billion € for inpatient critical disease, and 2 81 billion € for productivity losses</p>	<p>Sensitivity to Rt: 1) Rt 0.9, 2) Rt 1.3, 3) Rt 1.7, 4) Rt 2.1 Home-based SARS-COV-2 antigen testing: 1) 27 955 €, 2) 6 266 €, 3) 1 715 €, 4) 691 €</p> <p>ICER (Cost/death averted), Sensitivity to Rt: 1) Rt 0.9, 2) Rt 1.3, 3) Rt 1.7, 4) Rt 2.1 Home-based SARS-COV-2 antigen testing: 1) 3 819 966 €, 2) 1 135 666 €, 3) 385 173 €, 4) 157 246 €</p> <p>Sensitivity to the costs of testing With initial and confirmatory test costs set to their base-case values (4 5 € and 16 €), the intervention had an incremental cost-effectiveness ratio of 1 1 €million per death averted. Setting testing costs to the lowest (0 8 € and 7 9 €) and highest (0 8 € and 39 7 €) values in our estimated range yielded incremental cost-effectiveness ratios per death averted of 636 925 € and 1 75 € million, respectively.</p> <p>Sensitivity to Test Frequency Even under worst-case behavioral assumptions, cumulative infections could be cut more than 30% via the daily offer of testing.</p> <p>Sensitivity to Behavioral Factors Even under the worst-case behavioral scenario (25% participation; 25% isolation of persons with positive results; 33% rate of daily abandonment), more than 600 000 infections could be</p>
-------------	------------------------------	----------------	--	--	------------------------------	--	---	--

Online Supplementary Appendix I. Search Terms and Strategy

Database: Ovid MEDLINE(R) ALL <1946 to April 22, 2021>

Search Strategy:

-
- 1 Economics/ (27312)
 - 2 "costs and cost analysis"/ (49453)
 - 3 Cost allocation/ (2008)
 - 4 Cost-benefit analysis/ (84093)
 - 5 Cost control/ (21571)
 - 6 Cost savings/ (12170)
 - 7 Cost of illness/ (28590)
 - 8 Cost sharing/ (2590)
 - 9 "deductibles and coinsurance"/ (1780)
 - 10 Medical savings accounts/ (540)
 - 11 Health care costs/ (41105)
 - 12 Direct service costs/ (1203)
 - 13 Drug costs/ (16530)
 - 14 Employer health costs/ (1094)
 - 15 Hospital costs/ (11434)
 - 16 Health expenditures/ (21201)
 - 17 Capital expenditures/ (1996)
 - 18 Value of life/ (5745)
 - 19 exp economics, hospital/ (25059)
 - 20 exp economics, medical/ (14256)
 - 21 Economics, nursing/ (4002)
 - 22 Economics, pharmaceutical/ (2982)
 - 23 exp "fees and charges"/ (30654)
 - 24 (low adj cost).mp. (64981)
 - 25 (high adj cost).mp. (15874)
 - 26 (health?care adj cost\$).mp. (12946)
 - 27 (fiscal or funding or financial or finance).tw. (158630)
 - 28 (cost adj estimate\$).mp. (2411)
 - 29 (cost adj variable).mp. (46)
 - 30 (unit adj cost\$).mp. (2677)
 - 31 (economic\$ or pharmacoeconomic\$ or price\$ or pricing).tw. (327155)

- 32 Economic evaluation.mp. (10756)
- 33 (Cost?effectiveness analysis or CEA).mp. (24032)
- 34 (Cost?utility analysis or CUA).mp. (1284)
- 35 (Cost?benefit analysis or CBA).mp. (27076)
- 36 (Cost?consequence analysis or CCA).mp. (9017)
- 37 (Cost?minimi?sation analysis or CMA).mp. (4218)
- 38 (cost?outcome or marginal analysis).mp. (225)
- 39 exp Cost benefit analysis/ or exp budgets/ (97196)
- 40 investment\$.mp. or investments/ (45688)
- 41 or/1-40 (873724)
- 42 exp Coronavirus/ (68433)
- 43 exp Coronavirus Infections/ (82961)
- 44 (Coronavir* or nCov or covid or covid-19 or Middle East Respiratory Syndrome or MERS or Severe Acute Respiratory Syndrome or SARS).ti,ab,kf. (145090)
- 45 42 or 43 or 44 (152400)
- 46 41 and 45 (8520)
- 47 limit 46 to yr="2020-Current" (7555)
- 48 limit 47 to english language (7380)


Database: Embase <1974 to 2021 April 22>

Search Strategy:

-
- 1 Socioeconomics/ (143956)
 - 2 Cost benefit analysis/ (86950)
 - 3 Cost effectiveness analysis/ (158695)
 - 4 Cost of illness/ (19775)
 - 5 Cost control/ (70213)
 - 6 Economic aspect/ (116407)
 - 7 Financial management/ (115358)
 - 8 Health care cost/ (195273)
 - 9 Health care financing/ (13885)
 - 10 Health economics/ (33536)
 - 11 Hospital cost/ (22362)
 - 12 (fiscal or financial or finance or funding).tw. (222499)

- 13 Cost minimization analysis/ (3660)
- 14 (cost adj estimate\$).mp. (3676)
- 15 (cost adj variables\$).mp. (221)
- 16 (unit adj cost\$).mp. (4828)
- 17 investment\$.mp. or investments/ (57568)
- 18 or/1-17 (1008351)
- 19 exp coronavirus/ (34348)
- 20 exp coronavirus infections/ (116308)
- 21 (Coronavir* or nCov or covid or Middle East Respiratory Syndrome or MERS or Severe Acute Respiratory Syndrome or SARS).ti,ab,tw. (144234)
- 22 19 or 20 or 21 (156925)
- 23 18 and 22 (6304)
- 24 limit 23 to yr="2020-Current" (5439)
- 25 limit 24 to english language (5348)

Online Supplementary Appendix 2. Quality appraisal of the economic evaluation studies for estimating COVID-19 infection and strategies for preventing/mitigating COVID-19



1. Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al. Disease Control Priorities: Improving Health and Reducing Poverty. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2018 International Bank for Reconstruction and Development / The World Bank.; 2017.
2. ECDC. COVID-19 situation update worldwide, as of week 17, updated 5 May 2022. 2022
3. ECDC. Covid Statistic Measures 2021
4. ECDC. Latest risk assessment: further emergence and potential impact of the SARS-CoV-2 Omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 15 December 2021. 2021
5. Demirgüç-Kunt A, Lokshin M, Torre I. The sooner, the better: The economic impact of non-pharmaceutical interventions during the early stage of the COVID-19 pandemic. *Economics of Transition and Institutional Change*. 2021;29(4):551-73.
6. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *Jama*. 2020;324(15):1495-6.
7. López-Valcárcel BG, Vallejo-Torres L. The costs of COVID-19 and the cost-effectiveness of testing. *Applied Economic Analysis*. 2021;29(85):77-89.
8. Zhou L, Yan W, Li S, Yang H, Zhang X, Lu W, et al. Cost-Effectiveness of Interventions for the Prevention and Control of COVID-19: A Systematic Review and Meta-Analysis. SSRN. 2021;3944593.
9. Meltzer MI, Gambhir M, Atkins CY, Swerdlow DL. Standardizing scenarios to assess the need to respond to an influenza pandemic. *Clin Infect Dis*. 2015;60 Suppl 1(Suppl 1):S1-8.
10. WHO. Definitions: Emergencies. World Health Organization 2016. . 2016

11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ*. 2013;346:f1049.
13. CCEMG. EPPI-Centre Cost Converter. 2019.
14. JB I. The systematic review of economic evaluation evidence. *Implement Sci*. 2014:1-24.
15. Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, et al. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. *Asia Pac J Clin Oncol*. 2021;17(4):359-67.
16. Czernichow S, Bain SC, Capehorn M, Bøgelund M, Madsen ME, Yssing C, et al. Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model. *Clin Obes*. 2021;11(2):e12442.
17. Bain SC, Czernichow S, Bøgelund M, Madsen ME, Yssing C, McMillan AC, et al. Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. *Curr Med Res Opin*. 2021;37(1):27-36.
18. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, et al. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. *Int J Environ Res Public Health*. 2020;17(12).
19. Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. *Health Aff (Millwood)*. 2020;39(6):927-35.
20. Lee JK, Kwak BO, Choi JH, Choi EH, Kim JH, Kim DH. Financial Burden of Hospitalization of Children with Coronavirus Disease 2019 under the National Health Insurance Service in Korea. *J Korean Med Sci*. 2020;35(24):e224.

21. Kirigia JM, Deborah Muthuri RNK. The Present Value of Human Lives Lost Due to COVID-19 in the United Kingdom. *Pharmaceutical and Biomedical Research*. 2020;6(3):237-46.
22. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *J Med Econ*. 2021;24(1):308-17.
23. Gedik H. The cost analysis of inpatients with COVID-19. *Acta Medica Mediterranea*. 2020(6):3289-92.
24. Mallow PJ. Estimates of the value of life lost from COVID-19 in Ohio. *J Comp Eff Res*. 2021;10(4):281-4.
25. Chen J, Vullikanti A, Hoops S, Mortveit H, Lewis B, Venkatramanan S, et al. Medical costs of keeping the US economy open during COVID-19. *Sci Rep*. 2020;10(1):18422.
26. Chen J, Vullikanti A, Santos J, Venkatramanan S, Hoops S, Mortveit H, et al. Epidemiological and Economic Impact of COVID-19 in the US. *medRxiv*. 2020.
27. Thom H, Walker J, Vickerman P, Hollingworth W. Exploratory comparison of Healthcare costs and benefits of the UK's Covid-19 response with four European countries. *Eur J Public Health*. 2021;31(3):619-24.
28. Gandjour A. The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany. *Q Rev Econ Finance*. 2020.
29. Barnett-Howell Z, Watson OJ, Mobarak AM. The benefits and costs of social distancing in high- and low-income countries. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2021;115(7):807-19.
30. Zala D, Mosweu I, Critchlow S, Romeo R, McCrone P. Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom. *Value Health*. 2020;23(11):1432-7.
31. Miles DK, Heald AH, Stedman M. How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out? *Int J Clin Pract*. 2021;75(7):e14191.

32. Miles DK, Stedman M, Heald AH. "Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom. *Int J Clin Pract*. 2021;75(3):e13674.
33. Keogh-Brown MR, Jensen HT, Edmunds WJ, Smith RD. The impact of Covid-19, associated behaviours and policies on the UK economy: A computable general equilibrium model. *SSM Popul Health*. 2020;12:100651.
34. Shlomain A, Leshno A, Sklan EH, Leshno M. Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis. *Value Health*. 2021;24(5):607-14.
35. Kouidere A, Youssoufi LE, Ferjouchia H, Balatif O, Rachik M. Optimal Control of Mathematical modeling of the spread of the COVID-19 pandemic with highlighting the negative impact of quarantine on diabetics people with Cost-effectiveness. *Chaos Solitons Fractals*. 2021;145:110777.
36. Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. *Ann Intern Med*. 2021;174(6):803-10.
37. Currie J, Adamson J, Bowden B, Woolls J, Jones R, Healy B, et al. Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: a cost-minimisation analysis. *BMJ Open*. 2020;10(8):e038017.
38. Neilan AM, Losina E, Bangs AC, Flanagan C, Panella C, Eskibozkurt GE, et al. Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. *Clin Infect Dis*. 2021;73(9):e2908-e17.
39. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis. *Ann Intern Med*. 2021;174(4):501-10.
40. Baggett TP, Scott JA, Le MH, Shebl FM, Panella C, Losina E, et al. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. *JAMA Netw Open*. 2020;3(12):e2028195.

41. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. *JAMA Netw Open*. 2020;3(7):e2016818.
42. Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis. *Health Technol Assess*. 2021;25(21):1-68.
43. Risko N, Werner K, Offorjebe OA, Vecino-Ortiz AI, Wallis LA, Razzak J. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. *PLOS ONE*. 2020;15(10):e0240503.
44. Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. *J Allergy Clin Immunol Pract*. 2021;9(7):2658-68.e3.
45. Bartsch SM, O'Shea KJ, Wedlock PT, Strych U, Ferguson MC, Bottazzi ME, et al. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. *Am J Prev Med*. 2021;60(5):605-13.
46. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. *Vaccine*. 2021;39(7):1157-64.
47. Vernaz N, Agoritsas T, Calmy A, Gayet-Ageron A, Gold G, Perrier A, et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. *Swiss Med Wkly*. 2020;150:w20446.
48. Lee BY, Bartsch SM, Ferguson MC, Wedlock PT, O'Shea KJ, Siegmund SS, et al. The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *PLoS Comput Biol*. 2021;17(1):e1008470.
49. Águas R, Mahdi A, Shretta R, Horby P, Landray M, White L, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. *Nature Communications*. 2021;12(1):915.

50. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. *Adv Ther.* 2021;38(4):1811-31.
51. Ebigbo A, Römmele C, Bartenschlager C, Temizel S, Kling E, Brunner J, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. *Endoscopy.* 2021;53(2):156-61.
52. Losina E, Leifer V, Millham L, Panella C, Hyle EP, Mohareb AM, et al. College Campuses and COVID-19 Mitigation: Clinical and Economic Value. *Ann Intern Med.* 2021;174(4):472-83.
53. Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. *Lancet Infect Dis.* 2021;21(7):962-74.
54. Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore YPA, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. *Lancet Public Health.* 2021;6(3):e184-e91.
55. Gandjour A. How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. *Appl Health Econ Health Policy.* 2021;19(2):181-90.
56. Vardavas C, Nikitara K, Zisis K, Athanasakis K, Phalkey R, Leonardi-Bee J, et al. Cost-effectiveness of emergency preparedness measures in response to infectious respiratory disease outbreaks: a systematic review and econometric analysis. *BMJ Open.* 2021;11(4):e045113.
57. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *International Journal of Surgery.* 2020;78:185-93.

58. Vandepitte S, Alleman T, Nopens I, Baetens J, Coenen S, De Smedt D. Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review. *Value in Health*. 2021;24(11):1551-69.
59. Juneau C-E, Pueyo T, Bell M, Gee G, Collazzo P, Potvin L. Evidence-Based, Cost-Effective Interventions To Suppress The COVID-19 Pandemic: A Systematic Review. *medRxiv*. 2020:2020.04.20.20054726.